WO2010032434A1 - 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 - Google Patents
医療用複合有機化合物粉体、その製造方法ならびに懸濁液 Download PDFInfo
- Publication number
- WO2010032434A1 WO2010032434A1 PCT/JP2009/004596 JP2009004596W WO2010032434A1 WO 2010032434 A1 WO2010032434 A1 WO 2010032434A1 JP 2009004596 W JP2009004596 W JP 2009004596W WO 2010032434 A1 WO2010032434 A1 WO 2010032434A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- organic compound
- powder
- particle size
- average particle
- compound powder
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a medical composite organic compound powder containing poorly water-soluble organic compound particles, a method for producing the same, and a suspension in which the medical composite organic compound powder is dispersed.
- the medicinal component of the preparation In order for the medicinal component of the preparation to function effectively, the medicinal component needs to reach the target site through the blood vessels in the body.
- the thinnest capillary in the blood vessel is about 5 ⁇ m.
- the particle size of the organic compound is required to be smaller than 5 ⁇ m.
- the bioavailability of a preparation is extremely important in medicine and pharmaceuticals because it reduces the dosage and thereby reduces side effects on the living body.
- the bioavailability of a formulation is determined by the physicochemical properties of the drug, the dosage form, and the route of administration.
- oral preparations have the advantages of being easier and less painful than injection preparations (parenteral preparations), but have the disadvantage of a low bioavailability.
- Oral preparations enter the intestines via the stomach and duodenum, are absorbed into the blood mainly from the intestinal tract, and are sent to the liver through the portal vein.
- oral preparations pass through such a long route, some of them are decomposed by the action of gastric acid or the like, or are metabolized in the liver and converted into completely different substances.
- One of the main reasons why the bioavailability is low is that oral preparations are difficult to be absorbed from digestive organs such as the intestines.
- preparations have medicinal ingredients that are poorly water-soluble or water-insoluble organic compounds.
- preparations containing the above-mentioned poorly water-soluble or water-insoluble organic compound as a medicinal ingredient are prepared by dissolving the organic compound in an organic solvent and dispensing it, and by heating the organic compound to an emulsified state (for example, , Refer to Patent Documents 1 and 2), or a method of reducing the size of the organic compound to micron-order particles and mixing it with water.
- an organic solvent that dissolves an organic compound may cause a medically undesirable event, and it is required that such an organic solvent is not used as much as possible.
- many organic compounds having medicinal components have almost the same melting point and decomposition point. When the organic compound is dissolved by heating, the organic compound decomposes at the same time, and the organic compound is decomposed into the medicinal component. There is a risk of changing to something that cannot be. Furthermore, there is a problem that it is difficult to use a method of thermal dissolution for an organic compound having a high melting point.
- JP 2007-23051 A Special table 2003-531162 gazette JP 2003-286105 A Japanese Patent Application Laid-Open No. 11-1000031 JP-A-6-228454
- the solvent salt milling method is useful as a method for pulverizing organic pigments such as dioxazine and copper phthalocyanine
- the degree of pulverization and whether the pulverization method can be applied to medical organic compounds are discussed. It is unknown.
- an organic compound that is an active ingredient of a pharmaceutical product is required to be pulverized while maintaining its crystal form.
- dissolution of the organic compound in a liquid solution causes dissolution and re-elution even if the amount is extremely small.
- a liquid crystal and an amorphous form different from those before pulverization are generated, so that it is known that it is very difficult to select a liquid medium (Pharmaceutical Development and Technology Vol. 9, No.
- the present inventors tried to grind by mixing a salt with a medical organic compound and succeeded in finding a method capable of grinding to a useful level as a drug.
- the following improvements are required for miniaturization of medical organic compounds. That is, 1) further increasing the pulverization efficiency, 2) preventing re-aggregation of fine particles, and 3) preventing the recovery rate of nano-sized medical organic compounds from being lowered.
- a point is sought.
- the medical organic compound is refined to the nano level, it re-aggregates and the water-insoluble medical organic compound may be dissolved in the washing water due to the increase in the specific surface area.
- poorly water-soluble substances are classified into two types, those that do not dissolve in water and those that do not dissolve in water.
- the latter include those that can dissolve when sufficient time is spent, but are classified as poorly water-soluble substances when the dissolution time is unsuitable for industrial use.
- the specific surface area is increased by miniaturization, the contact surface with water increases and the dissolution rate may increase.
- the stably dispersed nanoparticles are very difficult to collect in the “filtration (separation) / water washing step” because of their fine form. This is because it passes through a filter or the like in the filtration step and does not settle sufficiently in the centrifugation step. Therefore, high crushing efficiency, high redispersibility, and high collection efficiency are mutually contradictory requirements.
- the present invention has been made to meet such demands, and an object of the present invention is to provide a drug that has low contamination of the grinding media, is safe, and has improved bioavailability.
- the present inventors have added and pulverized organic compound powder in addition to physiologically acceptable salts and physiologically acceptable polyols.
- the organic compound powder can be pulverized with high efficiency, and by removing the salt and the polyol after pulverization, the average particle diameter is very small while maintaining the crystal structure.
- the inventors have found that an organic compound powder in a form in which part or all of the particle surface is covered with a carboxyvinyl polymer can be produced, and the present invention has been completed.
- organic compound powders with excellent dispersibility and excellent collection efficiency can be produced by adding lecithin to the refined organic compound and mixing, and completed the present invention. I let you. In addition, when adding a lecithin, the presence or absence of the addition of a carboxy vinyl polymer is not ask
- the present invention relates to a pharmaceutical composite organic compound powder having an average particle diameter of 400 nm or less, a suspension having the powder, and a pulverization method for obtaining the powder. Further, the present invention provides a compound organic compound powder for pharmaceutical use having an average particle size of 400 nm or less, a suspension having the powder, and the powder by adding lecithin to the refined organic compound and carrying out a mixing treatment. The present invention relates to a manufacturing method for obtaining a body with high collection efficiency.
- the composite organic compound powder for pharmaceutical use of the present invention is a particle in which a part or all of the particle surface of a slightly water-soluble and crystalline organic compound is covered with a carboxyvinyl polymer and covered with the carboxyvinyl polymer.
- the average particle diameter converted from the BET specific surface area of the film is 400 nm or less.
- the organic compound is preferably fenofibrate, felbinac, pranlukast hydrate, miconazole, fluticasone propionate, indomethacin, amphotericin B, acyclovir, nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, prazosin hydrochloride, prednisolone , Cortisone acetate, dexamethasone, betamethasone, beclomethasone propionate, budesonide, fluocinolone acetonide, naproxen, ketoprofen, 7- (3,5-dimethoxy-4-hydroxycinnamoylamino) -3-octyloxy-4-hydroxy- 1-methyl-2 (1H) -quinolinone, phenytoin, phenacemide, ethotoin, primidone, diazepam, nitrazepam, clo
- the composite organic compound powder for pharmaceutical use is preferably a fenofibrate powder having an average particle diameter calculated from the BET specific surface area of 50 to 400 nm.
- the composite organic compound powder for pharmaceutical use is preferably a felbinac powder having an average particle diameter converted from the BET specific surface area of 50 to 400 nm.
- the pharmaceutical complex organic compound powder is preferably a pranlukast hydrate powder having an average particle size of 20 to 70 nm converted from the BET specific surface area.
- the pharmaceutical complex organic compound powder is preferably a miconazole powder having an average particle size calculated from the BET specific surface area of 50 to 300 nm.
- the composite organic compound powder for pharmaceutical use is preferably fluticasone propionate powder having an average particle diameter of 20 to 100 nm as calculated from the BET specific surface area.
- the pharmaceutical complex organic compound powder is preferably an indomethacin powder having an average particle size of 20 to 120 nm as calculated from the BET specific surface area.
- the composite organic compound powder for pharmaceutical use of the present invention further has lecithin on the surface of the carboxyvinyl polymer or organic compound particles.
- the present invention is a suspension obtained by dispersing the composite organic compound powder for pharmaceutical use of (9).
- a method for producing a pharmaceutical composite organic compound powder of the present invention comprises a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, a physiologically acceptable polyol, and a carboxy.
- a step of mixing the vinyl polymer with the organic compound powder and pulverizing the organic compound powder and a step of removing at least the salt and the polyol after the pulverization are included.
- the method for producing a pharmaceutical composite organic compound powder of the present invention further includes a step of adding lecithin during or after the pulverizing step.
- the organic compound particles are preferably fenofibrate, felbinac, pranlukast hydrate, miconazole, fluticasone propionate, indomethacin, amphotericin B, acyclovir, nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, prazosin hydrochloride, Prednisolone, cortisone acetate, dexamethasone, betamethasone, beclomethasone propionate, budesonide, fluocinolone acetonide, naproxen, ketoprofen, 7- (3,5-dimethoxy-4-hydroxycinnamoylamino) -3-octyloxy-4-hydroxy -1-Methyl-2 (1H) -quinolinone, phenytoin, phenacemide, ethotoin, primidone, diazepam, nitraze
- the salt is preferably sodium chloride, potassium chloride, ammonium chloride, sodium sulfate, magnesium sulfate, potassium sulfate, calcium sulfate, sodium malate, sodium citrate, disodium citrate, sodium dihydrogen citrate, 1 or more selected from the group consisting of potassium dihydrogen citrate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and dipotassium hydrogen phosphate.
- the polyol is preferably glycerin, propylene glycol or polyethylene glycol.
- the salt and the polyol are preferably sodium chloride and glycerin, respectively.
- the pharmaceutical composite organic compound powder of the present invention is composed of composite particles having lecithin on the surface of poorly water-soluble organic compound particles, or composite particles in which the organic compound and lecithin are combined at the nano level. .
- the average particle diameter determined by volume conversion of the composite particles constituting the powder is preferably 400 nm or less.
- the organic compound is preferably fenofibrate, felbinac, pranlukast hydrate, miconazole, fluticasone propionate, indomethacin, amphotericin B, acyclovir, nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, prazosin hydrochloride, prednisolone , Cortisone acetate, dexamethasone, betamethasone, beclomethasone propionate, budesonide, fluocinolone acetonide, naproxen, ketoprofen, 7- (3,5-dimethoxy-4-hydroxycinnamoylamino) -3-octyloxy-4-hydroxy- 1-methyl-2 (1H) -quinolinone, phenytoin, phenacemide, ethotoin, primidone, diazepam, nitrazepam, a
- the pharmaceutical complex organic compound powder is preferably a powder of at least one of amphotericin B, acyclovir or indomethacin having an average particle size of 50 to 250 nm.
- the present invention is a suspension obtained by dispersing at least one pharmaceutical complex organic compound powder of (17) to (19).
- the method for producing a composite organic compound powder for pharmaceutical use according to the present invention comprises mixing an organic compound powder having poor water solubility, a physiologically acceptable salt and a physiologically acceptable polyol. And a step of removing at least the salt and the polyol after the pulverization.
- the method for producing a pharmaceutical composite organic compound powder of the present invention further includes a step of adding lecithin during or after the step of pulverizing.
- the “average particle diameter converted from the BET specific surface area” is calculated by converting the value of the specific surface area measured by the BET flow method (one-point formula) to the diameter of the virtual spherical particles. .
- the conversion formula from the value of the specific surface area to the diameter is the following formula 1.
- D is an average particle diameter
- ⁇ is a solid density
- S is a specific surface area
- ⁇ is a shape factor. In the case of spherical particles, ⁇ is 6.
- the BET flow method is preferably a method for measuring the specific surface area by the following method.
- a mixed gas of nitrogen and helium is allowed to flow through the cell containing the sample to be measured, and the sample is cooled with liquid nitrogen. Then, only nitrogen gas is adsorbed on the surface of the sample. Next, when the cell is returned to room temperature, gas desorption occurs. In this gas desorption process, the ratio of nitrogen gas flowing through another detector becomes larger than the ratio of nitrogen gas in the mixed gas flowing through one detector. The difference between the signals of these detectors becomes the amount of adsorption, and the specific surface area can be measured.
- the melting point of the “poorly water-soluble medical organic compound” of the present invention is preferably 80 to 400 ° C.
- the melting point of the poorly water-soluble medical organic compound of the present invention is preferably 80 to 360 ° C., more preferably 80 to 320 ° C., and most preferably 80 to 280 ° C.
- the solubility of a poorly water-soluble organic compound in water can be about 1 mg / mL or less, preferably about 0.5 mg / mL at a normal medical organic compound handling temperature, for example, room temperature around 25 ° C. mL or less, more preferably 0.3 mg / mL or less, and most preferably 0.1 mg / mL or less.
- the “poorly water-soluble medical organic compound” of the present invention is preferably a crystalline poorly water-soluble medical organic compound.
- “crystalline” means a state in which molecules are regularly arranged, and whether or not a certain substance is crystalline is well known to those skilled in the art such as thermal analysis, X-ray diffraction, electron diffraction, and the like. You can know by the method.
- the crystalline poorly water-soluble medical organic compound used in the method of the present invention is preferably an organic compound having a clearer crystal form.
- the “slightly water-soluble medical organic compound” does not necessarily have to be crystalline and includes an amorphous organic compound.
- the poorly water-soluble medical organic compound may be a natural product or a synthetic product.
- natural products include organic compounds derived from animals, organic compounds derived from plants, or organic compounds derived from microorganisms such as yeast.
- the poorly water-soluble medical organic compound of the present invention may be one kind of organic compound or a mixture of two or more kinds of organic compounds.
- Examples of such poorly water-soluble medical organic compounds include fenofibrate, felbinac, pranlukast hydrate, miconazole, fluticasone propionate, indomethacin, amphotericin B, acyclovir, nifedipine, nicardipine, nimodipine, dipyridamole, disopyramide, Prazosin hydrochloride, prednisolone, cortisone acetate, dexamethasone, betamethasone, beclomethasone propionate, budesonide, fluocinolone acetonide, naproxen, ketoprofen, 7- (3,5-dimethoxy-4-hydroxycinnamoylamino) -3-octyloxy- 4-hydroxy-1-methyl-2 (1H) -quinolinone, phenytoin, phenacemide, ethotoin, primidone, diazepam, nitrazep
- the “medical composition” is not particularly limited as long as it is used for the purpose of treatment or prevention or diagnosis of humans or animals.
- the medical composition of the present invention may be administered to the body or surface of a human or animal, or treats blood, urine, etc. collected from a human or animal outside the body. Also good.
- Such medical compositions include antipyretic drugs, analgesics, anti-inflammatory drugs, gout drugs, hyperuricemia treatment drugs, sleeping drugs, sedative drugs, anxiolytic drugs, antipsychotic drugs, antidepressant drugs, anti-depressants Glaze, psychostimulant, antiepileptic drug, muscle relaxant, Parkinson's disease drug, autonomic nervous system drug, cerebral circulation metabolic drug, allergy drug, cardiotonic drug, antianginal drug, beta blocker, Ca Antagonist, antiarrhythmic, antidiuretic, diuretic, antihypertensive, peripheral circulatory disorder, hyperlipidemia, hypertensive, respiratory stimulant, bronchodilator, asthma, antitussive, expectorant , Chronic obstructive pulmonary disease treatment, peptic ulcer treatment, laxative, antidiarrheal / intestinal medication, diabetes drug, corticosteroid preparation, sex hormone preparation, osteoporosis drug, bone metabolism improving drug, vitamin preparation, Hematopoietic drugs
- the carboxyvinyl polymer covers a part of the particle surface of the poorly water-soluble and crystalline organic compound, but does not cover the entire surface of the particle, or completely covers the particle surface. Form may be sufficient.
- lecithin may be present directly on the surface of the organic compound particle or may be present on the surface of the carboxyvinyl polymer.
- physiologically acceptable means that it is considered that the substance can be ingested without causing any particular physiological problems, and a substance is a physiologically acceptable substance. This is appropriately determined depending on the species to be ingested, the mode of ingestion, and the like.
- physiologically acceptable solvents include substances approved as additives and solvents for pharmaceuticals and foods.
- FIG. 1 is an SEM photograph (magnification: 10,000 times) of the crushed powder of felbinac obtained under the conditions of Example 2.
- FIG. 2 is an SEM photograph (magnification: 20,000 times) in which a part of the visual field shown in FIG. 1 is enlarged.
- FIG. 3 is an SEM photograph (magnification: 10,000 times) of the crushed powder of felbinac obtained under the conditions of Comparative Example 2.
- FIG. 4 is an SEM photograph (magnification: 20,000 times) in which a part of the visual field shown in FIG. 3 is enlarged.
- FIG. 5 is an SEM photograph (magnification: 10,000 times) of a pulverized powder of fluticasone propionate obtained under the conditions of Example 5.
- FIG. 5 is an SEM photograph (magnification: 10,000 times) of a pulverized powder of fluticasone propionate obtained under the conditions of Example 5.
- FIG. 6 is an SEM photograph (magnification: 20,000 times) in which a part of the visual field shown in FIG. 5 is enlarged.
- FIG. 7 is an SEM photograph (magnification: 10,000 times) of a pulverized powder of fluticasone propionate obtained under the conditions of Comparative Example 5.
- FIG. 8 is an SEM photograph (magnification: 20,000 times) in which a part of the visual field shown in FIG. 7 is enlarged.
- the pharmaceutical compound organic compound powder is a partially water-soluble and crystalline organic compound particle surface partially or entirely covered with carboxyvinyl polymer, The average particle diameter converted from the BET specific surface area of the particles covered with the vinyl polymer is 400 nm or less. Furthermore, the pharmaceutical composite organic compound powder according to a preferred embodiment further has lecithin on the surface of the carboxyvinyl polymer or organic compound particles.
- the pharmaceutical composite organic compound powder according to this embodiment is a particle in a state having lecithin on the particle surface of the organic compound, or a state in which the organic compound and lecithin form a complex, Also included are those having an average particle size of 400 nm or less determined by volume conversion.
- Organic compounds used in medical composite organic compound powders include fenofibrate (melting point: 80 to 83 ° C), felbinac (melting point: 163 to 166 ° C), pranlukast hydrate ( Melting point: 231-235 ° C.), miconazole (melting point: 84-87 ° C.), fluticasone propionate (melting point: about 273 ° C.
- decomposition dexamethasone (melting point: about 45 ° C (decomposition)), betamethasone (melting point: about 240 ° C (decomposition)), beclomethasone propionate (melting point: about 208 ° C (decomposition)), budesonide (melting point: about 240 ° C (decomposition)), fluocinolone acetonide (Melting point: about 266-274 ° C.
- Simvastatin (melting point: 135-138 ° C), fluoxymesterone (melting point: 270-278 ° C), stanozolol (melting point: 230-242 ° C), Stradiol (melting point: 175 to 180 ° C.), chlormadinone acetate (melting point: 211 to 215 ° C.), falecalcitriol (melting point: about 143 ° C.), mazindol (melting point: about 177 to 184 ° C.
- composition chlorphenesin carbamate (melting point: 88-91 ° C.), dantrolene sodium (melting point: 200 ° C. or more (decomposition)), formoterol fumarate ( Melting point: about 138 ° C. (decomposition), atenolol (melting point: 153-156 ° C.), riluzole (melting point: about 118 ° C.), flumazenil (melting point: 198-202 ° C.), theophylline (melting point: 271-275 ° C. (decomposition)) ), Methotrexate (melting point: 185 to 204 ° C.
- Carboxyvinyl polymer A water-swellable vinyl polymer mainly composed of acrylic acid, also called “carbomer”, and is not particularly limited as long as it is commonly used in pharmaceuticals. Can be used in combination.
- carbomers different types of Mw, such as Carbopol (registered trademark) 934, Carbopol (registered trademark) 940, Carbopol (registered trademark) 980, Carbopol (registered trademark) 981, Carbopol (registered trademark) 2984, Carbopol (registered trademark).
- Lecithin is a compound comprising a fatty acid residue and a phosphate group and a basic compound or sugar bonded to the glycerin skeleton, and is also called “phosphatidylcholine”.
- soybeans, rapeseed and chicken eggs can be used. However, the type is not particularly limited.
- Lecithin is oily crude lecithin, powdered high-purity lecithin that has been defatted, fractionated lecithin with a higher ratio of specific components using solvents, chromatographic techniques, etc., fully or partially hydrogenated and purified
- There are many types such as hydrogenated lecithin with improved oxidative stability, and enzyme-decomposed lecithin obtained by enzymatic treatment of these lecithins and enzyme-modified lecithin, any of which can be used.
- a method for producing a pharmaceutical composite organic compound powder according to this embodiment comprises a poorly water-soluble and crystalline organic compound powder, a physiologically acceptable salt, It includes a step of mixing a physiologically acceptable polyol and a carboxyvinyl polymer to pulverize the organic compound powder, and a step of removing the salt and the polyol after the pulverization.
- the composite organic compound powder for pharmaceutical use according to a preferred embodiment includes a step of adding lecithin during or after the pulverizing step.
- the method for producing a pharmaceutical composite organic compound powder according to this embodiment comprises mixing a poorly water-soluble organic compound powder, a physiologically acceptable salt, and a physiologically acceptable polyol. And a step of pulverizing the organic compound powder and a step of removing at least the salt and the polyol after the pulverization. Furthermore, it preferably includes a step of adding lecithin during or after the pulverizing step.
- Polyol used in the production method according to the present embodiment is not particularly limited as long as it is a salt that can be ingested without causing any particular physiological problems.
- Physiologically acceptable polyols are preferably those having low solubility in salts, high solubility in water, low freezing points and / or high flash points.
- the physiologically acceptable polyol preferably has high solubility in water.
- polyol examples include glycerin, propylene glycol, polyethylene glycol, dipropylene glycol, and diethylene glycol, and are preferably propylene glycol or glycerin.
- the viscosity of the polyol is preferably 50 to 200,000 (dPa ⁇ S), more preferably 1,000 to 50,000 (dPa ⁇ S), and still more preferably 5,000 to 30,000. 000 (dPa ⁇ S).
- the amount of polyol used is preferably 0.7 to 50 parts by weight, more preferably 2 to 15 parts by weight, and more preferably 3 to 10 parts by weight with respect to 1 part by weight of the organic compound to be ground. More preferably it is.
- the kind of polyol to be used can be appropriately determined in consideration of the solubility of the organic compound to be ground.
- one kind of polyol may be used as the polyol, or two or more kinds of polyols may be mixed and used.
- the salt used in the production method according to the present embodiment is not particularly limited as long as it is a salt that can be ingested without causing any particular physiological problems.
- the physiologically acceptable salt preferably has a low solubility in polyols, a high solubility in water, and / or a hardness that is less hygroscopic and suitable for pulverization of organic compounds. Salt.
- a salt having two or more of these properties is more preferable.
- the solubility of the salt in the polyol is preferably 10 (mass / volume) or less. In the case where the removal of the salt is simplified after pulverization, a suitable salt is highly soluble in water.
- Suitable salts include, for example, sodium chloride, potassium chloride, ammonium chloride, sodium sulfate, magnesium sulfate, potassium sulfate, calcium sulfate, sodium malate, sodium citrate, disodium citrate, sodium dihydrogen citrate, citric acid
- potassium dihydrogen, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, and dipotassium hydrogen phosphate examples include sodium chloride, potassium chloride, magnesium sulfate, calcium sulfate, sodium citrate, sodium dihydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, preferably sodium chloride It is.
- the salt may be pulverized to adjust the particle size before mixing with the poorly water-soluble medical organic compound.
- the volume average particle diameter may be, for example, 5 to 300 ⁇ m, 10 to 200 ⁇ m, preferably 0.01 to 300 ⁇ m, more preferably 0.1 to
- the thickness is 100 ⁇ m, more preferably 0.5 to 50 ⁇ m, and most preferably 1 to 5 ⁇ m.
- the amount of the salt used is preferably 1 to 100 parts by weight, more preferably 5 to 50 parts by weight, and more preferably 10 to 30 parts by weight with respect to 1 part by weight of the organic compound. Further preferred.
- one type of salt may be used, or two or more types of salts may be mixed and used.
- the composite organic compound powder for medical use according to the present embodiment is preferably subjected to the “pulverization process”, “lecithin mixing process”, “filtration / water washing process” and “drying process” in this order.
- the “pulverization step” and the “lecithin mixing step” may be integrated into one step, and lecithin may be mixed into the pulverized particles while being pulverized.
- a dispersant is added to the medical composite organic compound powder obtained through the above steps and mixed with water as necessary. To do.
- the “grinding step”, “lecithin mixing step”, “filtration (separation) / water washing step” and “drying step” will be described.
- the pulverization apparatus used for wet pulverizing the organic compound is not particularly limited as long as it has the ability to make the organic compound fine by mechanical means.
- the pulverizer include commonly used pulverizers such as a kneader, a two-roll, a three-roll, a fret mill, a hoover marra, a disk blade kneading and dispersing machine, and a twin-screw extruder.
- the organic compound, salt and carboxyvinyl polymer into the pulverizer and knead while adding the polyol little by little.
- the viscosity at the time of kneading can be appropriately determined depending on the type of organic compound, salt, and polyol to be pulverized.
- the pulverization temperature can be appropriately determined in consideration of the organic compound to be pulverized, the pulverizer, and the like.
- the pulverization temperature is not particularly limited as long as it can reduce melting or decomposition of the organic compound, but is preferably ⁇ 50 to 50 ° C., more preferably ⁇ 20 to 30 ° C., and most preferably ⁇ 10 to 25 ° C. Further, the pulverization time can be appropriately determined in consideration of the organic compound to be pulverized, the pulverizing apparatus, and the like.
- the grinding time can be, for example, about 1 to 50 hours, preferably 3 to 30 hours, more preferably 5 to 20 hours, and most preferably 6 to 18 hours.
- the amount of carboxyvinyl polymer used is preferably 0.002 to 0.9 parts by mass, more preferably 0.005 to 0.4 parts by mass, with respect to 1 part by mass of the organic compound to be pulverized.
- the amount is preferably 0.03 to 0.07 parts by mass.
- the type of carboxyvinyl polymer to be used can be appropriately determined in consideration of the type of organic compound to be pulverized. Further, one kind of the carboxyvinyl polymer may be used, or two or more kinds having different Mw may be mixed and used.
- the mixing step can be performed by mixing lecithin after pulverization in the pulverizer or during pulverization and continuing kneading in the same pulverizer.
- another mixing apparatus can be prepared, the kneaded product after pulverization can be transferred to the mixing apparatus, and lecithin can be added thereto to perform the mixing step.
- the amount of lecithin used is preferably 0.01 to 10 parts by weight, more preferably 0.05 to 2 parts by weight, with respect to 1 part by weight of the organic compound to be ground. More preferably, it is 1.0 part by mass.
- Lecithin may be used alone, but a mixture of polyol and lecithin can also be added. In that case, the mixing ratio (weight ratio) of lecithin and polyol is 1 to 10 parts by mass of polyol, more preferably 1.5 to 5 parts by mass, and further preferably 2 to 4 parts by mass with respect to 1 part by mass of lecithin. is there.
- the solvent is preferably water, but a solvent other than water can also be used.
- the solvent other than water include a mixed solution of water and an organic solvent such as acetic acid, methanol, and ethanol.
- the filtration method is not specifically limited, It can perform by the well-known method normally used in order to filter the content of an organic compound. Examples of the filtration method include a vacuum filtration method, a pressure filtration method, and an ultrafiltration membrane method. Further, there is a centrifugal separation method as a method for removing salts and polyols as in the case of filtration.
- a specific method of centrifugation is to put the kneaded material after mixing lecithin in a solvent and uniformly mix using a homogenizer, etc., and then precipitate the finely pulverized organic compound in a centrifuge. Remove the clarification. By repeating this operation, the salt and polyol can be removed.
- the end point of washing can be determined by measuring the electrical conductivity of the supernatant. That is, for example, if the electrical conductivity of the supernatant is 10 ⁇ S / cm, the concentration of sodium chloride can be predicted to be about 5 ppm. Therefore, the electrical conductivity at the end point may be determined according to the characteristics of the substance.
- the finely pulverized particles of a medical composite organic compound usually have high surface energy, and thus are easily aggregated. Therefore, an additive for preventing secondary aggregation may be added after removing salts and the like.
- the secondary aggregation inhibitor include, for example, alkyl sulfate, N-alkyloylmethyl taurate, ethanol, glycerin, propylene glycol, sodium citrate, purified soybean lecithin, phospholipid, D-sorbitol, lactose, xylitol, gum arabic , Sucrose fatty acid ester, polyoxyethylene hydrogenated castor oil, polyoxyethylene fatty acid ester, polyoxyethylene glycol, polyoxyethylene sorbitan fatty acid ester, alkylbenzene sulfonate, sulfosuccinate ester salt, polyoxyethylene polyoxypropylene glycol, polyvinyl Pyrrolidone, polyvinyl alcohol, hydroxypropylcellulose, methylcellulose, hydroxy
- alkyl sulfates and N-alkyloylmethyl taurate are preferable, and sodium dodecyl sulfate and N-myristoyl methyl taurate are particularly preferable.
- One kind of secondary aggregation inhibitor may be used, or two or more kinds of secondary aggregation inhibitors may be mixed and used.
- the medical composite organic compound powder obtained by performing a drying treatment is used.
- the solvent used for removing salts and the like can be removed.
- the drying method is not particularly limited, and can be usually performed by a method used for drying an organic compound. Examples of the drying method include a vacuum drying method, a freeze drying method, a spray drying method, and a freeze spray drying method.
- the drying temperature and drying time in the drying are not particularly limited, but the drying should be performed at a low temperature in order to maintain the chemical stability of the medical composite organic compound particles and prevent secondary aggregation of the particles. It is preferable to carry out by a reduced pressure drying method, a freeze drying method, a spray drying method, or a freeze spray drying method.
- the range of the average particle diameter converted from the BET specific surface area of the fine particles constituting the composite organic compound powder for medical use obtained by the production method according to the present embodiment is preferably 20 to 400 nm, more preferably 20 It is ⁇ 300 nm or less, more preferably 50 to 150 nm.
- the medical composite organic compound powder obtained by the production method according to the present embodiment has excellent formulation characteristics and can be used as pharmaceuticals in various dosage forms.
- a solvent-containing solid hereinafter referred to as a wet cake
- a medical composite organic compound powder obtained by removing salt and polyol after pulverization is suspended in water and frozen. It can be prepared as porous particles of about 1 to 30 ⁇ m by spray drying.
- a small amount of a surfactant may be added to the water.
- a small amount of a volatile additive such as ethanol may be added.
- ethanol can be distilled off at the time of drying, so that irritation can be improved as compared with the case where a surfactant is added.
- an aqueous dispersion is prepared by adding a secondary aggregation inhibitor to the wet cake. be able to.
- the secondary aggregation inhibitor include known surfactants.
- the compounds mentioned in the secondary aggregation inhibitor that can be added after removing the salt and polyol can be used.
- An aqueous dispersion using a polymer such as an acrylic acid copolymer or a methacrylic acid copolymer as a secondary aggregation inhibitor can be used as a DDS agent.
- the aqueous dispersion can also be pulverized by vacuum drying, spray drying, freeze drying, freeze spray drying, or the like. Since the powder prepared in this way is excellent in redispersibility in water, it has excellent properties as an injection, an eye drop, and an oral preparation for use at the time of use.
- the composite organic compound powder for medical use can be dispersed in an oily substance and used for ointments, capsules, transdermal absorbents and the like.
- the oily substance is not particularly limited as long as it is a substance usually used in formulation. Examples of the oily substance include liquid paraffin, petrolatum, propylene glycol, glycerin, polyethylene glycol, vegetable oil and the like.
- the oily substance may be used alone, or two or more oily substances may be mixed and used. Moreover, you may use the apparatus etc. which are normally used at the time of oily substance dispersion preparation.
- Examples of the apparatus include a homogenizer, a homomixer, an ultrasonic disperser, a high-pressure homogenizer, a two-roll, a three-roll, a disk blade kneading disperser, and a twin screw extruder.
- Example 1 Crushing experiment of fenofibrate 0.1 g of fenofibrate (melting point: 80-83 ° C.) having an average particle diameter of 6,640 nm and ground sodium chloride (average) 1.6 g of particle diameter: 5 ⁇ m) and 0.005 g of carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) were mixed and mixed uniformly, and then 0.36 g of glycerin was gradually added dropwise to make the contents into a dough. The mixture was kneaded at 20 ° C. for 100 rotations and pulverized.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.073 g of pulverized powder having an average particle size of 338 nm.
- Example 2 Felbinac crushing experiment 0.1 g of felbinac (melting point: 163 to 166 ° C) having an average particle diameter of 34,000 nm and ground sodium chloride (average particle diameter: 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: Nikko Chemicals) 0.005 g were charged and mixed uniformly. Then, 0.33 g of glycerin was gradually added dropwise to keep the contents in a dough shape. The mixture was kneaded at 100 ° C. for 100 revolutions.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.081 g of pulverized powder having an average particle size of 207 nm.
- ferbinac grinding experiment 0.1 g of ferbinac (melting point: 163 to 166 ° C) having an average particle size of 34,000 nm and ground sodium chloride (average particle size: average) on a water-cooled Hoovermarler (manufactured by Imoto Seisakusho Co., Ltd.) (5 ⁇ m) 1.6 g was charged and mixed uniformly, and then 0.36 g of glycerin was gradually added dropwise to keep the contents in a dough shape, which was kneaded at 20 ° C. for 100 revolutions and pulverized.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.085 g of pulverized powder having an average particle diameter of 535 nm.
- Example 3 Crushing experiment of pranlukast hydrate Pranlukast hydrate having an average particle size of 1,088 nm (melting point: about 231 to 235 ° C. (decomposition)) on a water-cooled Hoovermarler (manufactured by Imoto Seisakusho Co., Ltd.) ) 0.1 g, 1.6 g of crushed sodium chloride (average particle size: 5 ⁇ m) and 0.005 g of carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) were mixed and uniformly mixed, and then 0.42 g of glycerin was gradually added.
- the mixture was dripped into the dough and the contents were kept in the form of a dough and kneaded at 20 ° C. for 100 revolutions. Then, the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. The obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.090 g of pulverized powder having an average particle diameter of 62 nm.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.098 g of pulverized powder having an average particle diameter of 73 nm.
- Example 4 Miconazole Grinding Experiment 0.1 g of miconazole (melting point: 84-87 ° C.) having an average particle size of 10,900 nm and ground sodium chloride (average particle size: average particle size: water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.) 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: Nikko Chemicals) 0.005 g were charged and mixed uniformly, then 0.345 g of glycerin was gradually added dropwise to keep the contents in a dough shape. The mixture was kneaded at 100 ° C. for 100 revolutions.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.058 g of pulverized powder having an average particle diameter of 142 nm.
- Example 5 Grinding experiment of fluticasone propionate 0.1 g of fluticasone propionate (melting point: about 273 ° C. (decomposition)) having an average particle size of 7,850 nm was pulverized and chlorinated in a water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.). Sodium (average particle size: 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) 0.005 g were charged and mixed uniformly, then glycerin 0.375 g was gradually added dropwise to knead the contents.
- Carbopol 980 carboxyvinyl polymer
- the mixture was kept in the shape and kneaded for 100 revolutions at 20 ° C. Then, the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. The obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.071 g of pulverized powder having an average particle diameter of 71 nm.
- the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water.
- the obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.075 g of pulverized powder having an average particle diameter of 114 nm.
- Indomethacin pulverization experiment 8 g of indomethacin (melting point: 155 to 162 ° C) having an average particle size of 3,960 nm and crushed sodium chloride (average particle size) in a 0.2 L kneader (decomposed type kneader, manufactured by Yoshida Seisakusho) : 5 ⁇ m) 170 g and carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) 0.5 g were charged and mixed uniformly, and then 36 g of glycerin was gradually injected to keep the contents in a dough shape. Time grinding was performed.
- FIGS. 1 and 2 show an SEM photograph (magnification: 10,000 times) of the ferbinac ground powder obtained in Example 2, and an enlarged SEM photograph (magnification: 20,000 times) of the SEM photograph.
- 3 and 4 are respectively an SEM photograph (magnification: 10,000 times) of the ferbinac ground powder obtained in Comparative Example 2 and an enlarged SEM photograph (magnification: 20,000) of the SEM photograph.
- FIG. 5 and FIG. 6 are SEM photographs (magnification: 10,000 times) of the ground powder of fluticasone propionate obtained in Example 5, respectively, and SEM photographs (magnifications) of a part of the SEM photograph. : 20,000 times)
- FIG. 7 and FIG. 8 are SEM photographs (magnification: 10,000 times) of the pulverized fluticasone propionate powder obtained in Comparative Example 5, respectively, and an enlarged S on the SEM photograph.
- M Photo show the (magnification 20,000 times).
- the average particle size of the powder before and after pulverization was measured using a BET specific surface area measuring device (Macsorb HM-1201, manufactured by Mountec Co., Ltd.). Moreover, the particle size of the particles in the suspension was measured using a particle size distribution measuring device (Delsa Nano S, manufactured by Beckman Coulter).
- D 50 is the particle diameter (referred to as the central particle diameter) of the integrated value 50% counted from the larger (or smaller) particle in the particle size distribution.
- D 90 is the diameter of a particle having an integrated value of 90% (referred to as 90% diameter) counted from the smaller particle in the particle size distribution.
- D V is a volume average particle diameter (referred to as an average particle diameter).
- Example 7 Grinding experiment of fenofibrate 0.1 g of fenofibrate (melting point: 80-83 ° C.) having an average particle diameter of 6,640 nm and ground sodium chloride (average particle) in a water-cooled Hoovermarler (manufactured by Imoto Seisakusho Co., Ltd.) (Diameter: 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) 0.005 g were mixed and mixed uniformly, and then 0.36 g of glycerin was gradually added dropwise to keep the contents in a dough shape. The mixture was kneaded at 20 ° C. for 100 revolutions.
- 0.1 g of a purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with the obtained pulverized kneaded product and kneaded at 20 ° C. for 50 revolutions. Then, the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. The obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.094 g of powder.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- Comparative Example 7 Fenofibrate Grinding Experiment To 0.05 g of the powder produced in Example 1, 5 g of 1% sodium dodecyl sulfate was added as a dispersant, and an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System) Was dispersed uniformly, and 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- the particle size distribution was found to be an average particle size (D V ) of 556.5 nm, a center particle
- the diameter (D 50 ) was 457.2 nm and the 90% diameter (D 90 ) was 742.6 nm.
- Comparative Example 8 Fenofibrate Grinding Experiment To 0.05 g of the powder prepared in Comparative Example 1, 5 g of 1% sodium dodecyl sulfate was added as a dispersant, and an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System) Was dispersed uniformly, and 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- the particle size distribution was found to be an average particle size (D V ) 629.5 nm, a center particle
- the diameter (D 50 ) was 893.6 nm
- the 90% diameter (D 90 ) was 1,867 nm.
- Felbinac crushing experiment 0.1 g of felbinac (melting point: 163 to 166 ° C.) having an average particle diameter of 34,000 nm and ground sodium chloride (average particle diameter: 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: Nikko Chemicals) 0.005 g were charged and mixed uniformly. Then, 0.33 g of glycerin was gradually added dropwise to keep the contents in a dough shape. The mixture was kneaded at 100 ° C. for 100 revolutions.
- 0.1 g of a purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with the obtained pulverized kneaded product and kneaded at 20 ° C. for 50 revolutions. Then, the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. The obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.106 g of powder.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- the particle size distribution was found to be an average particle size (D V ) of 5,618 nm, a center particle
- the diameter (D 50 ) was 273.0 nm
- the 90% diameter (D 90 ) was 10,321 nm.
- the particle size distribution was found to be an average particle size (D V ) 610.8 nm, a center particle
- the diameter (D 50 ) was 498.2 nm
- the 90% diameter (D 90 ) was 842.8 nm.
- Example 9 Crushing experiment of pranlukast hydrate Pranlukast hydrate having an average particle size of 1,088 nm (melting point: about 231 to 235 ° C. (decomposition)) in a water-cooled Hoovermarer (manufactured by Imoto Seisakusho Co., Ltd.) ) 0.1 g, 1.6 g of crushed sodium chloride (average particle size: 5 ⁇ m) and 0.005 g of carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) were mixed and uniformly mixed, and then 0.42 g of glycerin was gradually added.
- Hoovermarer manufactured by Imoto Seisakusho Co., Ltd.
- the mixture was dripped into the dough and the contents were kept in the form of a dough and kneaded at 20 ° C. for 100 revolutions. Further, 0.2 g of a purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with the obtained pulverized kneaded product and kneaded at 20 ° C. for 50 revolutions. The contents are then reduced to 50 mL of 0.1. The solution was placed in a mol / L acetic acid aqueous solution and dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. Were dried under reduced pressure to obtain 0.119 g of powder.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- the particle size distribution was found to be an average particle size (D V ) of 105.3 nm, a center particle
- the diameter (D 50 ) was 89.9 nm
- the 90% diameter (D 90 ) was 131.7 nm.
- the particle size distribution was found to be an average particle size (D V ) 43,804 nm, a center particle
- the diameter (D 50 ) was 38,306 nm
- the 90% diameter (D 90 ) was 39,845 nm.
- Comparative Example 12 Pulverukast Hydrate Crushing Experiment To 0.05 g of the powder prepared in Comparative Example 3, 5 g of 1% sodium dodecyl sulfate was added as a dispersant, and an ultrasonic device (UT-105, Sharp Using a manufacturing system), 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- an ultrasonic device UT-105, Sharp Using a manufacturing system
- the particle size distribution was found to be an average particle size (D V ) of 50,510 nm, a center particle
- the diameter (D 50 ) was 46,227 nm
- the 90% diameter (D 90 ) was 59,856 nm.
- Example 10 Miconazole Grinding Experiment 0.1 g of miconazole (melting point: 84 to 87 ° C.) having an average particle diameter of 10,900 nm and ground sodium chloride (average particle diameter: average particle diameter: manufactured by Imoto Seisakusho Co., Ltd.) 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: Nikko Chemicals) 0.005 g were charged and mixed uniformly, then 0.345 g of glycerin was gradually added dropwise to keep the contents in a dough shape. The mixture was kneaded at 100 ° C. for 100 rotations.
- 0.1 g of a purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with the obtained pulverized kneaded product and kneaded at 20 ° C. for 50 revolutions. Then, the contents are put into 50 mL of 0.1 mol / L acetic acid aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), followed by filtration and washing with water. The obtained wet cake was dried under reduced pressure at 30 ° C. to obtain 0.075 g of powder.
- an ultrasonic device UT-105, manufactured by Sharp Manufacturing System
- Example 13 Miconazole grinding experiment To 0.05 g of the powder prepared in Example 4, 5 g of 1% sodium dodecyl sulfate was added as a dispersant, and an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System) was used. Used to disperse uniformly, and 44.95 g of purified water was added to obtain 50.0 g of a suspension. As a result of measuring the particle size distribution of the obtained suspension using a particle size distribution measuring device (Delsa Nano S, manufactured by Beckman Coulter, Inc.), the particle size distribution was found to be an average particle size (D V ) of 155.5 nm, and a central particle. The diameter (D 50 ) was 136 nm, and the 90% diameter (D 90 ) was 193.6 nm.
- D V average particle size
- Example 11 Crushing Experiment of Fluticasone Propionate 0.1 g of fluticasone propionate (melting point: about 273 ° C. (decomposition)) having a mean particle size of 7,850 nm was pulverized into water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.). Sodium (average particle size: 5 ⁇ m) 1.6 g and carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) 0.005 g were charged and mixed uniformly, then glycerin 0.375 g was gradually added dropwise to knead the contents. The mixture was kept in the shape and kneaded for 100 revolutions at 20 ° C.
- Example 12 Indomethacin grinding experiment 8 g of indomethacin having an average particle diameter of 3,960 nm (melting point: 155 to 162 ° C.) and ground sodium chloride (average particle diameter) in a 0.2 L kneader (decomposed type kneader, manufactured by Yoshida Seisakusho) : 5 ⁇ m) 170 g and carboxyvinyl polymer 0.5 g were charged and uniformly mixed, and then 39 g of glycerin was gradually poured to keep the contents in a dough shape, and pulverized at 5 ° C. for 10 hours.
- L kneader decomposed type kneader, manufactured by Yoshida Seisakusho
- Comparative Example 18 Indomethacin Grinding Experiment To 0.05 g of the powder prepared in Comparative Example 6, 5 g of 1% N-myristoylmethyl taurine sodium was added as a dispersant, and an ultrasonic device (UT-105, Sharp Manufacturing System Co., Ltd.). And 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) 319.9 nm, a center particle
- the diameter (D 50 ) was 238.3 nm
- the 90% diameter (D 90 ) was 461.5 nm.
- Table 2 shows the results of Examples 7 to 12 and Comparative Examples 7 to 18. As shown in Table 2, it was found that the powder prepared by adding the carboxyvinyl polymer and lecithin has high redispersibility in water and the average particle size in the suspension is small. On the other hand, it was found that the powder prepared without adding lecithin was not easily dispersed in the suspension.
- the average particle diameter of the powder was measured using a BET specific surface area measuring apparatus (Macsorb HM-1201, manufactured by Mountec Co., Ltd.). Moreover, the particle size of the particles in the suspension was measured using a particle size distribution measuring device (Delsa Nano S, manufactured by Beckman Coulter).
- D 50 is the particle diameter (referred to as the central particle diameter) of the integrated value 50% counted from the larger (or smaller) particle in the particle size distribution.
- D 90 is the diameter of a particle having an integrated value of 90% (referred to as 90% diameter) counted from the smaller particle in the particle size distribution.
- D V is a volume average particle diameter (referred to as an average particle diameter).
- Example 13 Grinding and collection experiment of amphotericin B 0.1 g of amphotericin B (melting point: decomposed at 170 ° C. or higher) having an average particle size of 13,423 nm was ground in a water-cooled Hoovermarler (manufactured by Imoto Seisakusho Co., Ltd.). After charging 1.6 g of sodium (average particle size: 5 ⁇ m) and mixing uniformly, 0.36 g of glycerin is gradually added dropwise to keep the contents in a dough shape, kneaded at 20 ° C. for 100 revolutions, and pulverized. I did it.
- the average particle diameter of 13,423 nm of amphotericin B before pulverization is a value measured in the following manner.
- 0.01 g of amphotericin B was added with 5 g of 0.03% sodium lauryl sulfate as a dispersant, and the mixture was uniformly dispersed using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System Co., Ltd.). 44.99 g was added to obtain 50.0 g of a suspension.
- the particle size distribution of the resulting suspension was measured using a particle size distribution measuring device (Delsa Nano S, manufactured by Beckman Coulter, Inc.). As a result, the particle size distribution was an average particle diameter (D V ) of 13,423 nm, a central particle diameter (D 50 ) of 11,843 nm, and a 90% diameter (D 90 ) of 15,181 nm.
- 0.1 g of purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with the pulverized kneaded product obtained by pulverization using a water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.) Kneaded in a mortar. After that, the contents were put into 50 mL of 0.1 mol / L acetic acid aqueous solution, dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), and then centrifuged (6000 rpm). CN-2060 (manufactured by ASONE Corporation) for 10 minutes, and the supernatant was removed. After performing this operation 4 times, a wet cake was obtained.
- Example 14 Grinding experiment of acyclovir 0.1 g of acyclovir having an average particle diameter of 60,371 nm (melting point: decomposed at about 300 ° C) and ground sodium chloride (average particle) After adding 1.6 g (diameter: 5 ⁇ m) and mixing uniformly, 0.1 g of glycerin was gradually added dropwise to keep the contents in a dough shape, and kneaded at 20 ° C. for 100 revolutions.
- the average particle diameter 60,371 nm of acyclovir before pulverization is a value measured in the following manner.
- 0.01 g of acyclovir was added with 5 g of 0.03% sodium lauryl sulfate as a dispersant, and the mixture was uniformly dispersed using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), and purified water 44.99 g was added to obtain 50.0 g of a suspension.
- UT-105 Ultrasonic device
- purified water 44.99 g was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) of 60,371 nm, and a central particle.
- the diameter (D 50 ) was 52,997 nm
- the 90% diameter (D 90 ) was 69,371 nm.
- 0.2 g of a purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) was uniformly mixed with a pulverized kneaded product obtained by pulverization using a water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.) Kneaded in a mortar. Thereafter, the contents are put into 50 mL of an aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), and then centrifuged (6000 rpm, 10 minutes, CN- 2060, manufactured by ASONE Corporation), and the supernatant was removed. After performing this operation three times, the obtained wet cake was dried under reduced pressure at 30 ° C.
- Example 20 Acyclovir grinding experiment 0.1 g of acyclovir (melting point: decomposed at about 300 ° C) having an average particle size of 60,371 nm used in Example 14 was used in a water-cooled Hoover Muller (manufactured by Imoto Seisakusho Co., Ltd.). After charging 1.6 g of crushed sodium chloride (average particle size: 5 ⁇ m) and mixing uniformly, 0.1 g of glycerin is gradually added dropwise to keep the contents in a dough shape and kneaded at 20 ° C. for 100 revolutions. Then, pulverization was performed.
- the contents are put into 50 mL of an aqueous solution, and are dispersed uniformly using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System), and then centrifuged (6000 rpm, 10 minutes, CN- 2060, manufactured by ASONE Corporation), and the supernatant was removed.
- UT-105 manufactured by Sharp Manufacturing System
- centrifuged 6000 rpm, 10 minutes, CN- 2060, manufactured by ASONE Corporation
- Example 15 Indomethacin pulverization and recovery experiment Into a 2 L kneader (manufactured by Inoue Seisakusho), 38 g of indomethacin having an average particle size of 3,960 nm (melting point: 155 to 162 ° C) and 608 g of crushed sodium chloride (average particle size: 5 ⁇ m) were added. After charging and mixing uniformly, 78 g of glycerin was gradually poured to keep the contents in a dough shape, and pulverized at 5 ° C. for 2 hours. This kneaded product contains indomethacin having an average particle size of 154 nm.
- the average particle size of 154 nm of indomethacin in the kneaded product is a value measured in the following manner. Add 0.05 g of 0.1% lecithin / 0.03% sodium lauryl sulfate as a dispersant to 0.05 g of the kneaded material containing indomethacin, and use an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System). Then, 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) of 154 nm, a center particle size ( D 50 ) 118 nm, 90% diameter (D 90 ) 213 nm.
- the particle size distribution was found to be an average particle size (D V ) of 137 nm, a center particle size ( D 50 ) 122 nm and 90% diameter (D 90 ) 164 nm.
- the recovery rate was 69%.
- 0.01 g of the indomethacin-containing pulverized powder obtained was added with 5 g of 0.1% sodium lauryl sulfate as a dispersant, and uniform using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System).
- UT-105 manufactured by Sharp Manufacturing System
- purified water was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) of 1,484 nm, a center particle
- the diameter (D 50 ) was 201 nm
- the 90% diameter (D 90 ) was 4,012 nm. Since some of the particles were agglomerated, it is assumed that the difference between D V , D 50 , and D 90 was large.
- Example 16 Indomethacin pulverization and recovery experiment In a 2 L kneader (manufactured by Inoue Seisakusho), 38 g of indomethacin having an average particle diameter of 3,960 nm (melting point: 155 to 162 ° C), 608 g of crushed sodium chloride (average particle diameter: 5 ⁇ m), and After 1.9 g of carboxyvinyl polymer (Carbopol 980: manufactured by Nikko Chemicals) was charged and mixed uniformly, 78 g of glycerin was gradually poured to keep the contents in a dough shape, and pulverized at 5 ° C. for 2 hours. . This kneaded product contains indomethacin having an average particle size of 96 nm.
- the average particle diameter of 96 nm of indomethacin in the kneaded product is a value measured in the following manner. Add 0.05 g of 0.1% lecithin / 0.03% sodium lauryl sulfate as a dispersant to 0.05 g of the kneaded material containing indomethacin, and use an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System). Then, 44.95 g of purified water was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) of 96 nm, a center particle size ( D 50 ) 72 nm, 90% diameter (D 90 ) 142 nm.
- a portion of 532 g (amount containing 28 g of indomethacin) and 57 g of purified hydrogenated soybean lecithin-glycerin mixture (1: 3 weight ratio) were uniformly charged by pulverizing with a 2 L kneader (manufactured by Inoue Seisakusho). Mixed. Thereafter, about 10 g of the contents (containing 0.48 g of indomethacin) was put in 50 mL of purified water, dispersed uniformly with a homogenizer, and then centrifuged to remove salt and glycerin. This operation was repeated, and washing was performed until the electric conductivity of the supernatant after centrifugation was 10 ⁇ S / cm or less.
- the particle size distribution was found to be an average particle size (D V ) of 94 nm, a center particle size ( D 50 ) 79 nm and 90% diameter (D 90 ) 125 nm.
- the recovery rate was 67%.
- 0.01 g of the indomethacin-containing pulverized powder obtained was added with 5 g of 0.1% sodium lauryl sulfate as a dispersant, and uniform using an ultrasonic device (UT-105, manufactured by Sharp Manufacturing System).
- UT-105 manufactured by Sharp Manufacturing System
- purified water was added to obtain 50.0 g of a suspension.
- the particle size distribution was found to be an average particle size (D V ) of 202 nm, a center particle size ( D 50 ) 163 nm and 90% diameter (D 90 ) 269 nm.
- a water-insoluble organic compound can be refined more safely and easily than before, and further production efficiency (particle recovery rate) can be improved. It can be used in the field of medicine and diagnostics.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
Description
(4)また、医薬用複合有機化合物粉体は、好ましくは、BET比表面積から換算される平均粒子径が50~400nmのフェルビナク粉体である。
(5)また、医薬用複合有機化合物粉体は、好ましくは、BET比表面積から換算される平均粒子径が20~70nmのプランルカスト水和物粉体である。
(6)また、医薬用複合有機化合物粉体は、好ましくは、BET比表面積から換算される平均粒子径が50~300nmのミコナゾール粉体である。
(7)また、医薬用複合有機化合物粉体は、好ましくは、BET比表面積から換算される平均粒子径が20~100nmのプロピオン酸フルチカゾン粉体である。
(8)また、医薬用複合有機化合物粉体は、好ましくは、BET比表面積から換算される平均粒子径が20~120nmのインドメタシン粉体である。
1.医療用複合有機化合物粉体
好適な実施の形態に係る医薬用複合有機化合物粉体は、難水溶性かつ結晶性の有機化合物の粒子表面の一部若しくは全部がカルボキシビニルポリマーで覆われ、そのカルボキシビニルポリマーで覆われた状態の粒子のBET比表面積から換算される平均粒子径が400nm以下である。さらに、好適な実施の形態に係る医薬用複合有機化合物粉体は、カルボキシビニルポリマーまたは有機化合物粒子の表面に、さらにレシチンを有する。また、他にも、この実施の形態に係る医薬用複合有機化合物粉体は、有機化合物の粒子表面にレシチンを有する状態、若しくは有機化合物とレシチンとが複合体を形成した状態の粒子であり、体積換算により求められる平均粒子径が400nm以下のものも含む。
医療用複合有機化合物粉体に用いられる有機化合物としては、例えば、フェノフィブラート(融点:80~83℃)、フェルビナク(融点:163~166℃)、プランルカスト水和物(融点:231~235℃)、ミコナゾール(融点:84~87℃)、プロピオン酸フルチカゾン(融点:約273℃(分解))、インドメタシン(融点:155~162℃)、ニフェジピン(融点:172~175℃)、ニカルジピン(融点:136~138℃)、ニモジピン(融点:123~126℃)、ジピリダモール(融点:165~169℃)、ジソピラミド(融点:約204℃)、塩酸プラゾシン (融点:約275℃(分解))、プレドニゾロン(融点:約235℃(分解))、酢酸コルチゾン(融点:約240℃(分解))、デキサメタゾン (融点:約245℃(分解))、ベタメタゾン (融点:約240℃(分解))、プロピオン酸ベクロメタゾン(融点:約208℃(分解))、ブデソニド(融点:約240℃(分解))、フルオシノロンアセトニド (融点:約266~274℃(分解))、ナプロキセン(融点:154~158℃)、ケトプロフェン(融点:94~97℃)、7-(3,5-ジメトキシ-4-ヒドロキシシンナモイルアミノ)-3-オクチルオキシ-4-ヒドロキシ-1-メチル-2(1H)-キノリノン(以下、キノリノン誘導体という)(融点:186~187℃)、フェニトイン(融点:約296℃(分解))、フェナセミド(融点:214~216℃)、エトトイン(融点:90~95℃)、プリミドン(融点:279~284℃)、ジアゼパム(融点:130~134℃)、ニトラゼパム(融点:約227℃(分解))、クロナゼパム(融点:約240℃(分解))、ジギトキシン(融点:256~257℃(分解))、スピロノラクトン(融点:198~207℃)、トリアムテレン(融点:316℃)、クロルタリドン(融点:217℃)、ポリチアジド(融点:202.5℃)、ベンズチアジド(融点:231.5℃)、グリセオフルビン(融点:218~222℃)、ナリジクス酸(融点:225~231℃)、クロラムフェニコール(融点:149~153℃)、クロルゾキサジン (融点:188~192℃)、フェンプロバメート (融点:102~105.5℃)、メキタジン(融点:146~150℃)、ビスベンチアミン(融点:140~144℃)、トリアムシノロンアセトニド(融点:約290℃(分解))、フルコナゾール(融点:137~141℃)、リファンピシン(融点:183~188℃(分解)、ダカルバジン(融点:約204℃(分解))、マイトマイシンC(融点:300℃以上)、ビカルタミド(融点:190~195℃)、パクリタキセル(融点:220~223℃)、ウベニメクス(融点:約234℃(分解))、フマル酸クレマスチン (融点:176~180℃(分解))、エリスロマイシン(融点:133~138℃)、アムホテリシンB(融点:170℃)、セフィキシム(融点:約240℃(分解))、サラゾスルファピリジン(融点:240~249℃)、スパルフロキサシン(融点:266℃(分解)、チニダゾール(融点:125~129℃)、ビダラビン(融点:248~254℃(分解))、アシクロビル(融点:300℃(分解))、ミルリノン(融点:約317℃(分解))、ジゴキシン(融点:約230~265℃(分解))、ピンドロール(融点:169~173℃)、塩酸プロパフェノン(融点:172~175℃)、アムリノン(融点:約297℃(分解))、ヒドロクロロチアジド(融点:263~270℃(分解))、トランドラプリル(融点:123~126℃)、カンデサルタンシレキセチル(融点:163.6~164.1℃(分解))、ウラピジル(融点:156~161℃)、レセルピン(融点:264~265℃(分解))、メチルドパ(融点:295~298℃(分解))、ノルエピネフリン(融点:約191℃(分解))、シンバスタチン(融点:135~138℃)、フルオキシメステロン(融点:270~278℃)、スタノゾロール(融点:230~242℃)、エストラジオール(融点:175~180℃)、酢酸クロルマジノン(融点:211~215℃)、ファレカルシトリオール(融点:約143℃)、マジンドール(融点:約177~184℃(分解))、クエン酸シルデナフィル(融点:約200~201℃)、ミノキシジル(融点:248℃)、ドロペリドール(融点:約145~149℃)、クアゼパム(融点:148~151℃)、ペンタゾシン(融点:154℃)、プロペリシアジン(融点:113~118℃)、チミペロン(融点:200~203℃)、スルピリド(融点:175~182℃(分解))、アモキサピン(融点:178~182℃(分解))、マレイン酸リスリド(融点:約195℃(分解))、ニセルゴリン(融点:134~138℃(分解))、ビペリデン(融点:112~115℃)、レボドパ(融点:約275℃(分解))、カルバミン酸クロルフェネシン(融点:88~91℃)、ダントロレンナトリウム(融点:200℃以上(分解))、フマル酸ホルモテロール(融点:約138℃(分解))、アテノロール(融点:153~156℃)、リルゾール(融点:約118℃)、フルマゼニル(融点:198~202℃)、テオフィリン(融点:271~275℃(分解))、メトトレキサート(融点:185~204℃(分解))、アミドトリゾ酸(融点:291~308℃(分解))、シロスタゾール(融点:158~162℃)、アデニン(融点:約360℃(分解))、トルブタミド(融点:126~132℃)、ファモチジン(融点:約164℃(分解))、ウルソデスオキシコール酸(融点:200~204℃)、スリンダク(融点:180~187℃)、ピレノキシン(融点:約245℃(分解))、フルニソリド(融点:約243℃(分解))、ダナゾール(融点:223~227℃(分解))及びタクロリムス水和物(融点:約130~133℃)等が挙げられる。これらの有機化合物は、既知の方法により製造されたものを用いることができる。
アクリル酸を主体とした水膨潤性ビニルポリマーであり、別名、「カルボマー」といい、医薬品で通常用いられているものであれば特に制限されず、1種又は2種以上を組み合わせて使用できる。カルボマーとして、Mwの異なる複数種、例えば、Carbopol(登録商標)934、Carbopol(登録商標)940、Carbopol(登録商標)980、Carbopol(登録商標)981、Carbopol(登録商標)2984、Carbopol(登録商標)5984、Carbopol(登録商標)EDT 2050、Carbopol(登録商標)Ultrez 10、ハイビスワコー (登録商標)103、ハイビスワコー(登録商標)104、ハイビスワコー(登録商標)105などを用いることができる。
レシチンは、グリセリン骨格に脂肪酸残基とリン酸基、それに結合した塩基性化合物あるいは糖からなる化合物であり、別名、「ホスファチジルコリン」ともいう。一般的には、ダイズ、ナタネを起源とするもの、鶏卵を起源とするものを利用することができる。ただし、その種類については特に限定するものではない。レシチンは、油脂状のクルードレシチン、これを脱脂した粉末状の高純度レシチン、溶剤やクロマト技術等を用いて特定の成分の比率を高めた分別レシチン、完全又は部分的に水素添加し精製することで酸化安定性を高めた水添レシチン、またこれらのレシチンを酵素処理した酵素分解レシチンや酵素改質レシチン等の多種類に及ぶが、いずれを用いることもできる。
この実施の形態に係る医薬用複合有機化合物粉体の製造方法は、難水溶性かつ結晶性の有機化合物粉体と、生理的に許容される塩と、生理的に許容されるポリオールと、カルボキシビニルポリマーとを混合して、有機化合物粉体を粉砕する工程と、粉砕後に、塩およびポリオールを除去する工程とを含む。さらに、好適な実施の形態に係る医薬用複合有機化合物粉体は、粉砕する工程中若しくは該工程後に、レシチンを添加する工程を含む。また、この実施の形態に係る医薬用複合有機化合物粉体の製造方法は、難水溶性の有機化合物粉体と、生理的に許容される塩と、生理的に許容されるポリオールとを混合して、有機化合物粉体を粉砕する工程と、粉砕後に、少なくとも塩およびポリオールを除去する工程とを含む。さらに、好ましくは、上記粉砕する工程中若しくは粉砕する工程後に、レシチンを添加する工程を含む。
本実施の形態に係る製造方法に用いられるポリオールは、生理学上特に問題を生じることなく摂取することができる塩であれば特に限定されない。生理学的に許容されるポリオールとして、好ましくは、塩に対する溶解性の低いもの、水に対する溶解性が高いもの、凝固点が低いもの及び/又は引火点が高いものである。また、粉砕後の除去を簡便に行う場合には、生理学的に許容されるポリオールは、水に対する溶解性が高いことが好ましい。
本実施の形態に係る製造方法に用いられる塩は、生理学上特に問題を生じることなく摂取することができる塩であれば特に限定されない。生理学的に許容される塩として、好ましくは、ポリオールに対する溶解性が低い塩、水に対する溶解性が高い塩及び/又は吸湿性の少なく有機化合物の微粉砕化に適した硬さを有している塩である。塩として、より好ましくは、これらの性質の2以上を備える塩である。塩のポリオールに対する溶解度は、好ましくは、10(質量/容量)%以下である。また、粉砕後に塩の除去を簡便にする場合には、好適な塩は水に対する溶解性が高いものである。
本実施の形態にかかる医療用複合有機化合物粉体は、好適には、「粉砕工程」、「レシチンの混合工程」、「濾過・水洗工程」および「乾燥工程」を順に経て製造される。ただし、「粉砕工程」と「レシチンの混合工程」を統合した一つの工程とし、粉砕しながら粉砕粒子にレシチンを混合するようにしても良い。また、医療用複合有機化合物粉体を含む懸濁液を製造する場合には、上記各工程を経て得られた医療用複合有機化合物粉体に、必要に応じて分散剤を加えて水と混合する。以下、「粉砕工程」、「レシチンの混合工程」、「濾過(分離)・水洗工程」および「乾燥工程」について説明する。
本実施の形態に係る製造方法において、有機化合物を湿式粉砕するために用いられる粉砕装置は、機械的手段によって有機化合物を微細にできる能力を有するものであれば、特に制限なく用いることができる。該粉砕装置として、例えば、ニーダー、二本ロール、三本ロール、フレットミル、フーバーマーラ、円盤ブレード混練分散機、二軸エクストルーダー等の通常用いられている粉砕装置を挙げることができる。
レシチンは、粉砕中もしくは粉砕終了後の混練物と混合される。なお、この混練物に、カルボキシビニルポリマーが含まれていなくても良い。混合工程は、粉砕装置にて粉砕した後若しくは粉砕中にレシチンを混合して、同じ粉砕装置内で混練を継続することにより行うことができる。その他、混合用の別の装置(混合装置)を用意して、粉砕後の混練物を当該混合装置に移し、そこにレシチンを加えて混合工程を行うこともできる。レシチンの使用量は、粉砕対象である有機化合物1質量部に対して、0.01~10質量部であることが好ましく、0.05~2質量部であることがより好ましく、0.1~1.0質量部であることがさらに好ましい。レシチンは単独でも良いが、ポリオールとレシチンの混和物を加えることもできる。その場合、レシチンとポリオールとの混合比(重量比)は、レシチン1質量部に対してポリオール1~10質量部、より好ましくは1.5~5質量部、さらに好ましくは2~4質量部である。
レシチンの混合後、濾過および水洗を行い、少なくとも塩及びポリオールを除去することにより、所望の大きさに微粉砕した医療用複合有機化合物粉体を得る。具体的には、レシチン混合後の混練物を、溶媒中に入れて、ホモジナイザー等を用いて均一に混合した後、濾過及び水洗を行うことにより、塩およびポリオールを除去することができる。該混練物を均一に混合する際に使用する溶媒は、ポリオールおよび塩が溶解し易く、かつ微粉砕された有機化合物が溶解し難い溶媒であって、かつ、生理学的に許容される溶媒であれば、特に限定されるものではない。該溶媒は、水が好ましいが、水以外の溶媒も使用することができる。該水以外の溶媒として、例えば、酢酸、メタノール、エタノール等の有機溶媒と水との混合液がある。また、濾過方法は、特に限定されるものではなく、通常、有機化合物の含有物を濾過するために用いられる公知の方法で行うことができる。該濾過方法として、例えば、減圧濾過法、加圧濾過法、限外濾過膜法がある。また、濾過と同様に塩およびポリオールを除去する方法として、遠心分離法がある。遠心分離の具体的な方法は、レシチン混合後の混練物を、溶媒中に入れて、ホモジナイザー等を用いて均一に混合した後、遠心分離機にて微粉砕された有機化合物を沈降させ、上澄を除去する。この操作を繰り返すことにより、塩及びポリオールを除去できる。上澄液の電気伝導度を測定することにより、洗浄の終点を求めることができる。すなわち、例えば、上澄液の電気伝導度が10μS/cmであれば、塩化ナトリウムの濃度は約5ppmと予測できるので、物質の特性に合わせて、終点の電気伝導度を決めればよい。
塩及びポリオールを除去(完全に除去していない場合でも低減できていれば、「除去」という)した後、乾燥処理を行うことにより得られた医療用複合有機化合物粉体から、塩等の除去に用いた溶媒を除去することができる。該乾燥方法は、特に限定されるものではなく、通常、有機化合物を乾燥するために用いられる方法で行うことができる。該乾燥方法として、例えば、減圧乾燥法、凍結乾燥法、噴霧乾燥法、凍結噴霧乾燥法等がある。該乾燥における乾燥温度や乾燥時間等は特に制限されるものではないが、医療用複合有機化合物粒子の化学的安定性の保持及び粒子の二次凝集を防止するめに、該乾燥は低温で行うことが好ましく、減圧乾燥法、凍結乾燥法、噴霧乾燥法、凍結噴霧乾燥法で行うことが好ましい。
本実施の形態に係る製造方法により得られる医療用複合有機化合物粉体を構成する微粒子のBET比表面積から換算される平均粒子径の範囲としては、好ましくは20~400nm、より好ましくは20~300nm以下であり、更に好ましくは50~150nmである。
まず、カルボキシビニルポリマーを加えた粉砕実験について説明する。粉砕前後の乾燥粉末の平均粒径は、BET式比表面積測定装置(Macsorb HM-1201型、マウンテック社製)を用いて測定したBET比表面積を前述の式(1)により換算して求めた。また、粉砕前後の粉体の観察には、走査型電子顕微鏡(Scanning Electron Microscope: SEM、VE-7800型、キーエンス社製)を用いた。
水冷式フーバーマーラー(株式会社井元製作所製)に、平均粒子径6,640nmのフェノフィブラート(融点:80~83℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで、均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径338nmの粉砕パウダー0.073gを得た。
カルボキシビニルポリマーを添加していない点を除き、実施例1と同一条件にてフェノフィブラートを粉砕した。その結果、平均粒子径672nmの粉砕パウダー0.075gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径34,000nmのフェルビナク(融点:163~166℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.33gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径207nmの粉砕パウダー0.081gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径34,000nmのフェルビナク(融点:163~166℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径535nmの粉砕パウダー0.085gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径1,088nmのプランルカスト水和物(融点:約231~235℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.42gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径62nmの粉砕パウダー0.090gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径1,088nmのプランルカスト水和物(融点:約231~235℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径73nmの粉砕パウダー0.098gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径10,900nmのミコナゾール(融点:84~87℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.345gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径142nmの粉砕パウダー0.058gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径10,900nmのミコナゾール(融点:84~87℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで均一に混合した後、グリセリン0.33gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径358nmの粉砕パウダー0.060gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径7,850nmのプロピオン酸フルチカゾン(融点:約273℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.375gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径71nmの粉砕パウダー0.071gを得た。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径7,850nmのプロピオン酸フルチカゾン(融点:約273℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで均一に混合した後、グリセリン0.33gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径114nmの粉砕パウダー0.075gを得た。
0.2Lニーダー(分解型ニーダー、吉田製作所製)に、平均粒子径3,960nmのインドメタシン(融点:155~162℃)8g、粉砕した塩化ナトリウム(平均粒子径:5μm)170g及びカルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.5gを仕込んで均一に混合した後、グリセリン36gを徐々に注入し内容物をこね粉状に保って、5℃で10時間粉砕を行なった。その後、内容物を1Lの0.1mol/L酢酸水溶液中に入れ、ホモジナイザーで均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径58.5nmのインドメタシンの粉砕パウダー7gを得た。
0.2Lニーダー(分解型ニーダー、吉田製作所製)に、平均粒子径3,960nmのインドメタシン(融点:155~162℃)8g、粉砕した塩化ナトリウム(平均粒子径:5μm)170gを仕込んで均一に混合した後、グリセリン35.5gを徐々に注入し内容物をこね粉状に保って、5℃で8時間粉砕を行なった。その後、内容物を1Lの0.1mol/L酢酸水溶液中に入れ、ホモジナイザーで均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、平均粒子径141nmのインドメタシンの粉砕パウダー7gを得た。
次に、カルボキシビニルポリマーおよびレシチンを添加した粉砕実験について説明する。粉砕前後の粉末の平均粒径の測定は、BET式比表面積測定装置(Macsorb HM-1201型、マウンテック社製)を用いて行った。また、懸濁液中の粒子の粒径は、粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて測定した。「D50」は、粒度分布において粒子の大きい方から(あるいは小さい方から)数えて積算値50%の粒子の直径(中心粒子径という)である。「D90」は、粒度分布において粒子の小さい方から数えて積算値90%の粒子の直径(90%径という)である。「DV」は、体積平均粒径(平均粒子径という)である。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径6,640nmのフェノフィブラート(融点:80~83℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。さらに、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)0.1gを均一に混合し、20℃で50回転混練した。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー0.094gを得た。次に、得られたフェノフィブラート含有パウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)159.2nm、中心粒子径(D50)135.1nm、90%径(D90)199.6nmであった。
実施例1で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)556.5nm、中心粒子径(D50)457.2nm、90%径(D90)742.6nmであった。
比較例1で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)629.5nm、中心粒子径(D50)893.6nm、90%径(D90)1,867nmであった。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径34,000nmのフェルビナク(融点:163~166℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.33gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。さらに、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)0.1gを均一に混合し、20℃で50回転混練した。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー0.106gを得た。次に、得られたフェルビナク含有パウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)147.1nm、中心粒子径(D50)121.5nm、90%径(D90)192.3nmであった。
実施例2で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)5,618nm、中心粒子径(D50)273.0nm、90%径(D90)10,321nmであった。
比較例2で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)610.8nm、中心粒子径(D50)498.2nm、90%径(D90)842.8nmであった。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径1,088nmのプランルカスト水和物(融点:約231~235℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.42gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。さらに、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)0.2gを均一に混合し、20℃で50回転混練した。その後、内容物を50mLの0.1
mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー0.119gを得た。次に、得られたプランルカスト水和物含有パウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)105.3nm、中心粒子径(D50)89.9nm、90%径(D90)131.7nmであった。
実施例3で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)43,804nm、中心粒子径(D50)38,306nm、90%径(D90)39,845nmであった。
比較例3で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、を加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)50,510nm、中心粒子径(D50)46,227nm、90%径(D90)59,856nmであった。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径10,900nmのミコナゾール(融点:84~87℃)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.345gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し粉砕を行なった。さらに、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)0.1gを均一に混合し、20℃で50回転混練した。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー0.075gを得た。次に、得られたミコナゾール含有パウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)144.9nm、中心粒子径(D50)126.5nm、90%径(D90)182nmであった。
実施例4で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)155.5nm、中心粒子径(D50)136nm、90%径(D90)193.6nmであった。
比較例4で作製したパウダー0.05gに、分散剤として1%ドデシル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)20,059nm、中心粒子径(D50)17,562nm、90%径(D90)22,729nmであった。
水冷式フーバーマーラー(株式会社井元製作所製)に平均粒子径7,850nmのプロピオン酸フルチカゾン(融点:約273℃(分解))0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6g、カルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)0.005gを仕込んで均一に混合した後、グリセリン0.375gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。さらに、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)0.15gを均一に混合し、20℃で50回転混練した。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー0.092gを得た。次に、得られたプロピオン酸フルチカゾン含有パウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)96nm、中心粒子径(D50)79nm、90%径(D90)127.2nmであった。
実施例5で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)902.3nm、中心粒子径(D50)126.2nm、90%径(D90)2,129nmであった。
比較例5で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)3,508nm、中心粒子径(D50)3,315nm、90%径(D90)4,406nmであった。
0.2Lニーダー(分解型ニーダー、吉田製作所製)に、平均粒子径3,960nmのインドメタシン(融点:155~162℃)8g、粉砕した塩化ナトリウム(平均粒子径:5μm)170g及びカルボキシビニルポリマー0.5gを仕込んで均一に混合した後、グリセリン39gを徐々に注入し内容物をこね粉状に保って、5℃で10時間粉砕を行なった。その後、得られた粉砕混練物に精製水添大豆レシチン-グリセリン混和物(1:3重量比)16gおよびグリセリン23gを均一に混合し、10℃で1時間混練した。その後、内容物を1Lの0.1mol/L酢酸水溶液中に入れ、ホモジナイザーで均一に分散させた後、濾過、水洗し、得られたウェットケーキを30℃の減圧下で乾燥し、パウダー11.1gを得た。次に、得られたインドメタシン含有パウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)103nm、中心粒子径(D50)83.9nm、90%径(D90)139.2nmであった。
実施例6で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)123.7nm、中心粒子径(D50)99.7nm、90%径(D90)166.3nmであった。
比較例6で作製したパウダー0.05gに、分散剤として1%N-ミリストイルメチルタウリンナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.95gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)319.9nm、中心粒子径(D50)238.3nm、90%径(D90)461.5nmであった。
次に、粉砕粒子にレシチンを添加したものの捕集効率の改善実験について説明する。特記する場合を除き、粉末の平均粒径の測定は、BET式比表面積測定装置(Macsorb HM-1201型、マウンテック社製)を用いて行った。また、懸濁液中の粒子の粒径は、粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて測定した。「D50」は、粒度分布において粒子の大きい方から(あるいは小さい方から)数えて積算値50%の粒子の直径(中心粒子径という)である。「D90」は、粒度分布において粒子の小さい方から数えて積算値90%の粒子の直径(90%径という)である。「DV」は、体積平均粒径(平均粒子径という)である。
水冷式フーバーマーラー(株式会社井元製作所製)に、平均粒子径13,423nmのアムホテリシンB(融点:170℃以上で分解)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで、均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。
水冷式フーバーマーラー(株式会社井元製作所製)に、実施例13にて用いた平均粒子径13,423nmのアムホテリシンB(融点:170℃以上で分解)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで、均一に混合した後、グリセリン0.36gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの0.1mol/L酢酸水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させたが、粉砕された粒子は、遠心分離後に浮遊して回収できなかった。また、濾過を実施しても、粒子が透過してしまい、回収できなかった。
水冷式フーバーマーラー(株式会社井元製作所製)に、平均粒子径60,371nmのアシクロビル(融点:約300℃で分解)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで、均一に混合した後、グリセリン0.1gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。
水冷式フーバーマーラー(株式会社井元製作所製)に、実施例14にて用いた平均粒子径60,371nmのアシクロビル(融点:約300℃で分解)0.1g、粉砕した塩化ナトリウム(平均粒子径:5μm)1.6gを仕込んで、均一に混合した後、グリセリン0.1gを徐々に滴下し内容物をこね粉状に保って、20℃で100回転混練し、粉砕を行なった。その後、内容物を50mLの水溶液中に入れ、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散させた後、遠心分離(6000rpm、10分間、CN-2060,アズワン株式会社製)し、上澄を除去した。この操作を繰り返し実施すると、沈殿物は徐々に少なくなり、3回実施すると沈降物はみとめられなくなった。
2Lニーダー(井上製作所製)に、平均粒子径3,960nmのインドメタシン(融点:155~162℃)38gおよび粉砕した塩化ナトリウム(平均粒子径:5μm)608gを仕込んで均一に混合した後、グリセリン78gを徐々に注入し内容物をこね粉状に保って、5℃で2時間粉砕を行なった。この混練物は平均粒子径154nmのインドメタシンを含む。
実施例15にて得られた粉砕混練物の一部約10g(インドメタシン0.51g含む量)を50mLの精製水中に入れ、ホモジナイザーで均一に分散させた後、遠心分離し、塩およびグリセリンを除いた。この操作を繰り返し、遠心後の上澄み液の電気電導度が10μS/cm以下になるまで洗浄した。遠心分離洗浄は、6回実施した(4μS/cm)。得られたウェットケーキを30℃の減圧下で乾燥し、粉砕パウダー0.35g(インドメタシン含量0.35g)を得た。回収率は69%であった。また、得られたインドメタシン含有粉砕パウダー0.01gに、分散剤として0.1%ラウリル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.99gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)1,484nm、中心粒子径(D50)201nm、90%径(D90)4,012nmであった。一部粒子が凝集していたため、DV、D50、D90の差が大きい結果となったものと推察される。
2Lニーダー(井上製作所製)に、平均粒子径3,960nmのインドメタシン(融点:155~162℃)38g、粉砕した塩化ナトリウム(平均粒子径:5μm)608g及びカルボキシビニルポリマー(カーボポール980:日光ケミカルズ製)1.9gを仕込んで均一に混合した後、グリセリン78gを徐々に注入し内容物をこね粉状に保って、5℃で2時間粉砕を行なった。この混練物は平均粒子径96nmのインドメタシンを含む。
実施例16の粉砕混練物の一部約10g(インドメタシン0.54g含む量)を50mLの精製水中に入れ、ホモジナイザーで均一に分散させた後、遠心分離し、塩およびグリセリンを除いた。この操作を繰り返し、遠心後の上澄み液の電気電導度が10μS/cm以下になるまで洗浄した。遠心分離洗浄は、6回実施した(7μS/cm)。得られたウェットケーキを30℃の減圧下で乾燥し、粉砕パウダー0.36g(インドメタシン含量0.36g)を得た。回収率は67%であった。また、得られたインドメタシン含有粉砕パウダー0.01gに、分散剤として0.1%ラウリル硫酸ナトリウム5gを加え、超音波装置(UT-105、シャープマニファクチャリングシステム社製)を使用して、均一に分散し、精製水44.99gを加えて縣濁液50.0gを得た。粒度分布測定装置(Delsa Nano S、ベックマンコールター社製)を用いて、得られた懸濁液の粒度分布を測定した結果、当該粒度分布は、平均粒子径(DV)202nm、中心粒子径(D50)163nm、90%径(D90)269nmであった。
Claims (22)
- 難水溶性かつ結晶性の有機化合物の粒子表面の一部若しくは全部がカルボキシビニルポリマーで覆われ、
上記カルボキシビニルポリマーで覆われた状態の粒子のBET比表面積から換算される平均粒子径が400nm以下である医薬用複合有機化合物粉体。 - 前記有機化合物は、フェノフィブラート、フェルビナク、プランルカスト水和物、ミコナゾール、プロピオン酸フルチカゾン、インドメタシン、アムホテリシンB、アシクロビル、ニフェジピン、ニカルジピン、ニモジピン、ジピリダモール、ジソピラミド、塩酸プラゾシン、プレドニゾロン、酢酸コルチゾン、デキサメタゾン、ベタメタゾン、プロピオン酸ベクロメタゾン、ブデソニド、フルオシノロンアセトニド、ナプロキセン、ケトプロフェン、7-(3,5-ジメトキシ-4-ヒドロキシシンナモイルアミノ)-3-オクチルオキシ-4-ヒドロキシ-1-メチル-2(1H)-キノリノン、フェニトイン、フェナセミド、エトトイン、プリミドン、ジアゼパム、ニトラゼパム、クロナゼパム、ジギトキシン、スピロノラクトン、トリアムテレン、クロルタリドン、ポリチアジド、ベンズチアジド、グリセオフルビン、ナリジクス酸、クロラムフェニコール、クロルゾキサジン、フェンプロバメート、メキタジン、ビスベンチアミン、マイトマイシンC、ビカルタミド、パクリタキセル、ウベニメクス、ダカルバジン、フルコナゾール、リファンピシン、トリアムシノロンアセトニド、フマル酸クレマスチン、酢酸コルチゾン、デキサメタゾン、ザフィルルカスト、ジヒドロコレステロール、β―カロテン、没食子酸プロピル、桂皮酸、サッカリン、葉酸、及び、マルトールからなる群より選ばれる1以上である、請求項1に記載の医薬用複合有機化合物粉体。
- 前記BET比表面積から換算される平均粒子径が50~400nmのフェノフィブラート粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 前記BET比表面積から換算される平均粒子径が50~400nmのフェルビナク粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 前記BET比表面積から換算される平均粒子径が20~70mのプランルカスト水和物粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 前記BET比表面積から換算される平均粒子径が50~300nmのミコナゾール粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 前記BET比表面積から換算される平均粒子径が20~100nmのプロピオン酸フルチカゾン粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 平均粒子径が20~120nmのインドメタシン粉体である請求項2に記載の医薬用複合有機化合物粉体。
- 前記カルボキシビニルポリマーまたは前記有機化合物の粒子表面に、さらにレシチンを有することを特徴とする請求項1から8のいずれか1項に記載の医薬用複合有機化合物粉体。
- 請求項9に記載の医薬用複合有機化合物粉体を分散してなる懸濁液。
- 難水溶性かつ結晶性の有機化合物粉体と、生理的に許容される塩と、
生理的に許容されるポリオールと、カルボキシビニルポリマーとを混合して上記有機化合物粉体を粉砕する工程と、
粉砕後に、少なくとも上記塩および上記ポリオールを除去する工程と、
を含む、医薬用複合有機化合物粉体の製造方法。 - 前記粉砕する工程中若しくは該工程後に、さらに、レシチンを添加する工程を含む請求項11に記載の医薬用複合有機化合物粉体の製造方法。
- 前記有機化合物は、フェノフィブラート、フェルビナク、プランルカスト水和物、ミコナゾール、プロピオン酸フルチカゾン、インドメタシン、アムホテリシンB、アシクロビル、ニフェジピン、ニカルジピン、ニモジピン、ジピリダモール、ジソピラミド、塩酸プラゾシン、プレドニゾロン、酢酸コルチゾン、デキサメタゾン、ベタメタゾン、プロピオン酸ベクロメタゾン、ブデソニド、フルオシノロンアセトニド、ナプロキセン、ケトプロフェン、7-(3,5-ジメトキシ-4-ヒドロキシシンナモイルアミノ)-3-オクチルオキシ-4-ヒドロキシ-1-メチル-2(1H)-キノリノン、フェニトイン、フェナセミド、エトトイン、プリミドン、ジアゼパム、ニトラゼパム、クロナゼパム、ジギトキシン、スピロノラクトン、トリアムテレン、クロルタリドン、ポリチアジド、ベンズチアジド、グリセオフルビン、ナリジクス酸、クロラムフェニコール、クロルゾキサジン、フェンプロバメート、メキタジン、ビスベンチアミン、マイトマイシンC、ビカルタミド、パクリタキセル、ウベニメクス、ダカルバジン、フルコナゾール、リファンピシン、トリアムシノロンアセトニド、フマル酸クレマスチン、酢酸コルチゾン、デキサメタゾン、ザフィルルカスト、ジヒドロコレステロール、β―カロテン、没食子酸プロピル、桂皮酸、サッカリン、葉酸、及び、マルトールからなる群より選ばれる1以上である、請求項11または請求項12に記載の医薬用複合有機化合物粉体の製造方法。
- 前記塩は、塩化ナトリウム、塩化カリウム、塩化アンモニウム、硫酸ナトリウム、硫酸マグネシウム、硫酸カリウム、硫酸カルシウム、リンゴ酸ナトリウム、クエン酸ナトリウム、クエン酸二ナトリウム、クエン酸二水素ナトリウム、クエン酸二水素カリウム、リン酸二水素ナトリウム、リン酸二水素カリウム、リン酸水素二ナトリウム、及びリン酸水素二カリウムからなる群より選ばれる1以上である、請求項11または請求項12に記載の医薬用複合有機化合物粉体の製造方法。
- 前記ポリオールは、グリセリン、プロピレングリコールまたはポリエチレングリコールである請求項11または請求項12に記載の医薬用複合有機化合物粉体の製造方法。
- 前記塩が塩化ナトリウムであり、前記ポリオールがグリセリンである請求項11または請求項12に記載の医薬用複合有機化合物粉体の製造方法。
- 難水溶性の有機化合物の粒子表面にレシチンを有する複合体粒子、または当該有機化合物とレシチンとがナノレベルで複合した複合体粒子から成り、
体積換算により求められる平均粒子径が400nm以下である医薬用複合有機化合物粉体。 - 前記有機化合物は、フェノフィブラート、フェルビナク、プランルカスト水和物、ミコナゾール、プロピオン酸フルチカゾン、インドメタシン、アムホテリシンB、アシクロビル、ニフェジピン、ニカルジピン、ニモジピン、ジピリダモール、ジソピラミド、塩酸プラゾシン、プレドニゾロン、酢酸コルチゾン、デキサメタゾン、ベタメタゾン、プロピオン酸ベクロメタゾン、ブデソニド、フルオシノロンアセトニド、ナプロキセン、ケトプロフェン、7-(3,5-ジメトキシ-4-ヒドロキシシンナモイルアミノ)-3-オクチルオキシ-4-ヒドロキシ-1-メチル-2(1H)-キノリノン、フェニトイン、フェナセミド、エトトイン、プリミドン、ジアゼパム、ニトラゼパム、クロナゼパム、ジギトキシン、スピロノラクトン、トリアムテレン、クロルタリドン、ポリチアジド、ベンズチアジド、グリセオフルビン、ナリジクス酸、クロラムフェニコール、クロルゾキサジン、フェンプロバメート、メキタジン、ビスベンチアミン、マイトマイシンC、ビカルタミド、パクリタキセル、ウベニメクス、ダカルバジン、フルコナゾール、リファンピシン、トリアムシノロンアセトニド、フマル酸クレマスチン、酢酸コルチゾン、デキサメタゾン、ザフィルルカスト、ジヒドロコレステロール、β―カロテン、没食子酸プロピル、桂皮酸、サッカリン、葉酸、及び、マルトールからなる群より選ばれる1以上である、請求項17に記載の医薬用複合有機化合物粉体。
- 前記平均粒子径が50~250nmのアムホテリシンB、アシクロビルまたはインドメタシンの内の少なくともいずれか1種類の粉体である請求項18に記載の医薬用複合有機化合物粉体。
- 請求項17から請求項19のいずれか1つに記載の医薬用複合有機化合物粉体を分散してなる懸濁液。
- 難水溶性の有機化合物粉体と、生理的に許容される塩と、生理的に許容されるポリオールとを混合して上記有機化合物粉体を粉砕する工程と、
粉砕後に、少なくとも上記塩および上記ポリオールを除去する工程と、
を含む、医薬用複合有機化合物粉体の製造方法。 - 前記粉砕する工程中若しくは該工程後に、さらに、レシチンを添加する工程を含む請求項21に記載の医薬用複合有機化合物粉体の製造方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/063,026 US20110165259A1 (en) | 2008-09-19 | 2009-09-15 | Composite organic compound powder for medical use, method for producing same and suspension of same |
CA2737543A CA2737543C (en) | 2008-09-19 | 2009-09-15 | Composite organic compound powder for medical use and production method and suspension of the same |
MX2011002847A MX2011002847A (es) | 2008-09-19 | 2009-09-15 | Polvo de compuesto organico combinado para uso medico y metodo de produccion y suspension del mismo. |
EP09814279.7A EP2345426B1 (en) | 2008-09-19 | 2009-09-15 | Composite organic compound powder for medical use, method for producing same and suspension of same |
JP2010529625A JP5536654B2 (ja) | 2008-09-19 | 2009-09-15 | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 |
RU2011114292/15A RU2535017C2 (ru) | 2008-09-19 | 2009-09-15 | Композитный порошок из органического вещества для применения в медицине, способ его получения и его суспензия |
CN200980135720.6A CN102149410B (zh) | 2008-09-19 | 2009-09-15 | 医疗用复合有机化合物粉体及其制造方法以及悬浮液 |
KR1020117008410A KR101455446B1 (ko) | 2008-09-19 | 2009-09-15 | 의료용 복합 유기 화합물 분체, 그 제조 방법 및 현탁액 |
ES09814279.7T ES2467676T3 (es) | 2008-09-19 | 2009-09-15 | Polvo de un compuesto orgánico combinado para uso médico, método para producir el mismo y suspensión del mismo |
IL211121A IL211121A (en) | 2008-09-19 | 2011-02-08 | Compound organic compound powder for medical use, its method of manufacture and expansion |
US14/010,602 US9782484B2 (en) | 2008-09-19 | 2013-08-27 | Method for producing a composite organic compound powder for medical use |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008-241855 | 2008-09-19 | ||
JP2008241855 | 2008-09-19 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/063,026 A-371-Of-International US20110165259A1 (en) | 2008-09-19 | 2009-09-15 | Composite organic compound powder for medical use, method for producing same and suspension of same |
US14/010,602 Division US9782484B2 (en) | 2008-09-19 | 2013-08-27 | Method for producing a composite organic compound powder for medical use |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010032434A1 true WO2010032434A1 (ja) | 2010-03-25 |
Family
ID=42039283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/004596 WO2010032434A1 (ja) | 2008-09-19 | 2009-09-15 | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20110165259A1 (ja) |
EP (1) | EP2345426B1 (ja) |
JP (1) | JP5536654B2 (ja) |
KR (1) | KR101455446B1 (ja) |
CN (1) | CN102149410B (ja) |
CA (1) | CA2737543C (ja) |
ES (1) | ES2467676T3 (ja) |
IL (1) | IL211121A (ja) |
MX (1) | MX2011002847A (ja) |
PT (1) | PT2345426E (ja) |
RU (1) | RU2535017C2 (ja) |
TW (1) | TWI440479B (ja) |
WO (1) | WO2010032434A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013103956A (ja) * | 2011-11-10 | 2013-05-30 | Nippon Shokubai Co Ltd | 有機結晶 |
US20130236516A1 (en) * | 2010-11-02 | 2013-09-12 | Teikoku Seiyaku Co., Ltd. | Felbinac-Containing External Patch |
WO2013168437A1 (ja) | 2012-05-11 | 2013-11-14 | 株式会社アクティバスファーマ | 有機化合物ナノ粉体、その製造方法ならびに懸濁液 |
WO2016181935A1 (ja) * | 2015-05-08 | 2016-11-17 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103664773A (zh) * | 2013-12-18 | 2014-03-26 | 南京易亨制药有限公司 | 米力农的制备方法和精制方法 |
JP6921759B2 (ja) | 2015-06-04 | 2021-08-18 | クリティテック・インコーポレイテッド | 捕集装置および使用法 |
DK3439635T3 (da) | 2016-04-04 | 2021-03-08 | Crititech Inc | Formuleringer til behandling af fast tumor |
SG11201909840TA (en) | 2017-06-09 | 2019-11-28 | Crititech Inc | Treatment of epithelial cysts by intracystic injection of antineoplastic particles |
BR112019022720A2 (pt) | 2017-06-14 | 2020-05-12 | Crititech, Inc. | Métodos para tratar distúrbios pulmonares |
CN111278436A (zh) | 2017-10-03 | 2020-06-12 | 克里蒂泰克公司 | 局部递送抗肿瘤颗粒与全身递送免疫治疗剂相结合用于治疗癌症 |
CN110859675B (zh) * | 2019-10-21 | 2021-07-09 | 昆山洁宏无纺布制品有限公司 | 一种广谱长效抗菌医用手术包 |
CN112557573B (zh) * | 2020-12-31 | 2023-05-05 | 成都普康生物科技有限公司 | 一种测定aeea-aeea含量的方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
JPH03131355A (ja) * | 1989-10-17 | 1991-06-04 | Sankyo Co Ltd | 難溶性化合物の湿式粉砕方法 |
JPH04295420A (ja) * | 1991-01-25 | 1992-10-20 | Sterling Winthrop Inc | 表面変性薬物微小粒子 |
JPH06228454A (ja) | 1991-03-07 | 1994-08-16 | Toyo Ink Mfg Co Ltd | β型ジオキサジン顔料の製造法 |
JPH11100317A (ja) | 1997-07-26 | 1999-04-13 | Ciba Specialty Chem Holding Inc | Uv−防御剤組成物 |
JP2003286105A (ja) | 2002-03-27 | 2003-10-07 | Kumiai Chem Ind Co Ltd | 顆粒状水和剤 |
JP2003531162A (ja) | 2000-04-20 | 2003-10-21 | スカイファーマ・カナダ・インコーポレーテッド | 改善された水不溶性薬剤粒子の処理 |
JP2003342493A (ja) * | 2002-05-27 | 2003-12-03 | Konica Minolta Holdings Inc | 有機化合物の精製方法 |
JP2005008806A (ja) * | 2003-06-20 | 2005-01-13 | Toyo Ink Mfg Co Ltd | β型銅フタロシアニン顔料の製造方法 |
WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
JP2006255519A (ja) * | 2005-03-15 | 2006-09-28 | Masumi Kusunoki | 媒体循環型粉砕装置 |
JP2007023051A (ja) | 1993-03-05 | 2007-02-01 | Pfizer Health Ab | 生物活性剤の粒子およびその製造方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
IL111477A (en) * | 1994-10-31 | 1999-07-14 | Makhteshim Chem Works Ltd | Stable lycophene concentrates and process for their preparation |
JP2791317B2 (ja) * | 1995-12-26 | 1998-08-27 | 株式会社三和化学研究所 | 多層フィルム製剤 |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7255733B2 (en) | 2003-06-20 | 2007-08-14 | Toyo Ink Mfg. Co., Ltd. | Process for the production of β type copper phthalocyanine pigment and a use thereof |
DE602004012262T2 (de) * | 2003-06-26 | 2009-03-12 | Dainippon Ink And Chemicals, Inc. | Benzimidazolonverbindung |
KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
EP1621200A1 (en) * | 2004-07-26 | 2006-02-01 | Fournier Laboratories Ireland Limited | Pharmaceutical combinations containing an inhibitor of platelet aggregation and a fibrate |
MXPA04008735A (es) * | 2004-09-09 | 2006-03-13 | Gcc Technology And Processes S | Composiciones de mortero mejoradas a base de clinker ultra-fino, arena refinada y aditivos quomicos. |
JP2008524239A (ja) * | 2004-12-15 | 2008-07-10 | エラン ファーマ インターナショナル リミティド | ナノ粒子のタクロリムス製剤 |
DE102005016873A1 (de) * | 2005-04-12 | 2006-10-19 | Magforce Nanotechnologies Ag | Nanopartikel-Wirstoff-Konjugate |
WO2007007403A1 (ja) * | 2005-07-13 | 2007-01-18 | Miyoshi Kasei, Inc. | 表面処理粉体及びこれを含有する化粧料 |
US20070178051A1 (en) * | 2006-01-27 | 2007-08-02 | Elan Pharma International, Ltd. | Sterilized nanoparticulate glucocorticosteroid formulations |
TWI405590B (zh) | 2007-04-06 | 2013-08-21 | Activus Pharma Co Ltd | 微粉碎化有機化合物粒子之製法 |
-
2009
- 2009-09-15 RU RU2011114292/15A patent/RU2535017C2/ru active
- 2009-09-15 PT PT98142797T patent/PT2345426E/pt unknown
- 2009-09-15 WO PCT/JP2009/004596 patent/WO2010032434A1/ja active Application Filing
- 2009-09-15 JP JP2010529625A patent/JP5536654B2/ja active Active
- 2009-09-15 CN CN200980135720.6A patent/CN102149410B/zh active Active
- 2009-09-15 EP EP09814279.7A patent/EP2345426B1/en active Active
- 2009-09-15 CA CA2737543A patent/CA2737543C/en active Active
- 2009-09-15 MX MX2011002847A patent/MX2011002847A/es active IP Right Grant
- 2009-09-15 US US13/063,026 patent/US20110165259A1/en not_active Abandoned
- 2009-09-15 KR KR1020117008410A patent/KR101455446B1/ko active IP Right Grant
- 2009-09-15 ES ES09814279.7T patent/ES2467676T3/es active Active
- 2009-09-18 TW TW098131589A patent/TWI440479B/zh active
-
2011
- 2011-02-08 IL IL211121A patent/IL211121A/en active IP Right Grant
-
2013
- 2013-08-27 US US14/010,602 patent/US9782484B2/en active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0366613A (ja) * | 1989-08-04 | 1991-03-22 | Tanabe Seiyaku Co Ltd | 難溶性薬物の超微粒子化法 |
JPH03131355A (ja) * | 1989-10-17 | 1991-06-04 | Sankyo Co Ltd | 難溶性化合物の湿式粉砕方法 |
JPH04295420A (ja) * | 1991-01-25 | 1992-10-20 | Sterling Winthrop Inc | 表面変性薬物微小粒子 |
JPH06228454A (ja) | 1991-03-07 | 1994-08-16 | Toyo Ink Mfg Co Ltd | β型ジオキサジン顔料の製造法 |
JP2007023051A (ja) | 1993-03-05 | 2007-02-01 | Pfizer Health Ab | 生物活性剤の粒子およびその製造方法 |
JPH11100317A (ja) | 1997-07-26 | 1999-04-13 | Ciba Specialty Chem Holding Inc | Uv−防御剤組成物 |
JP2003531162A (ja) | 2000-04-20 | 2003-10-21 | スカイファーマ・カナダ・インコーポレーテッド | 改善された水不溶性薬剤粒子の処理 |
JP2003286105A (ja) | 2002-03-27 | 2003-10-07 | Kumiai Chem Ind Co Ltd | 顆粒状水和剤 |
JP2003342493A (ja) * | 2002-05-27 | 2003-12-03 | Konica Minolta Holdings Inc | 有機化合物の精製方法 |
JP2005008806A (ja) * | 2003-06-20 | 2005-01-13 | Toyo Ink Mfg Co Ltd | β型銅フタロシアニン顔料の製造方法 |
WO2006087919A1 (ja) * | 2005-01-28 | 2006-08-24 | Takeda Pharmaceutical Company Limited | 難水溶性物質含有微細化組成物 |
JP2006255519A (ja) * | 2005-03-15 | 2006-09-28 | Masumi Kusunoki | 媒体循環型粉砕装置 |
Non-Patent Citations (2)
Title |
---|
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 9, no. 1, 2004, pages 1 - 13 |
See also references of EP2345426A4 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130236516A1 (en) * | 2010-11-02 | 2013-09-12 | Teikoku Seiyaku Co., Ltd. | Felbinac-Containing External Patch |
US9833417B2 (en) * | 2010-11-02 | 2017-12-05 | Teikoku Seiyaku Co., Ltd. | Felbinac-containing external patch |
JP2013103956A (ja) * | 2011-11-10 | 2013-05-30 | Nippon Shokubai Co Ltd | 有機結晶 |
WO2013168437A1 (ja) | 2012-05-11 | 2013-11-14 | 株式会社アクティバスファーマ | 有機化合物ナノ粉体、その製造方法ならびに懸濁液 |
US9278071B2 (en) | 2012-05-11 | 2016-03-08 | Activus Pharma Co., Ltd. | Organic compound nano-powder, method for producing the same and suspension |
WO2016181935A1 (ja) * | 2015-05-08 | 2016-11-17 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
JPWO2016181935A1 (ja) * | 2015-05-08 | 2018-02-22 | 株式会社アクティバスファーマ | グルココルチコステロイドのナノ微粒子を含有する水性懸濁液剤 |
US10588913B2 (en) | 2015-05-08 | 2020-03-17 | Activus Pharma Co., Ltd. | Aqueous suspension agent containing glucocorticosteroid nanoparticles |
US11376262B2 (en) | 2015-05-08 | 2022-07-05 | Activus Pharma Co., Ltd. | Method of treating an inflammatory or infectious disease |
IL255452B (en) * | 2015-05-08 | 2022-08-01 | Activus Pharma Co Ltd | Aqueous suspension containing glucocorticosteroid nanoparticles |
Also Published As
Publication number | Publication date |
---|---|
TW201014615A (en) | 2010-04-16 |
US9782484B2 (en) | 2017-10-10 |
IL211121A (en) | 2014-09-30 |
CN102149410B (zh) | 2014-05-14 |
CN102149410A (zh) | 2011-08-10 |
JPWO2010032434A1 (ja) | 2012-02-02 |
CA2737543A1 (en) | 2010-03-25 |
ES2467676T3 (es) | 2014-06-12 |
EP2345426A4 (en) | 2012-01-11 |
JP5536654B2 (ja) | 2014-07-02 |
EP2345426B1 (en) | 2014-03-05 |
US20110165259A1 (en) | 2011-07-07 |
RU2535017C2 (ru) | 2014-12-10 |
US20140038931A1 (en) | 2014-02-06 |
RU2011114292A (ru) | 2012-10-27 |
MX2011002847A (es) | 2011-04-07 |
KR20110063830A (ko) | 2011-06-14 |
EP2345426A1 (en) | 2011-07-20 |
PT2345426E (pt) | 2014-06-09 |
TWI440479B (zh) | 2014-06-11 |
CA2737543C (en) | 2015-01-06 |
IL211121A0 (en) | 2011-04-28 |
KR101455446B1 (ko) | 2014-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5536654B2 (ja) | 医療用複合有機化合物粉体、その製造方法ならびに懸濁液 | |
JP5317960B2 (ja) | 微粉砕化有機化合物粒子の製造方法 | |
JP2010047579A (ja) | セルロース系表面安定剤を用いたヒト免疫不全ウイルス(hiv)プロテアーゼ阻害剤のナノ結晶製剤及びそのような製剤の製造方法 | |
Ali et al. | Development and clinical trial of nano-atropine sulfate dry powder inhaler as a novel organophosphorous poisoning antidote | |
Liu | Nanocrystal formulation for poorly soluble drugs | |
Ye et al. | Nanosuspensions of a new compound, ER-β005, for enhanced oral bioavailability and improved analgesic efficacy | |
WO2018118929A1 (en) | Pharmaceutical formulations of suvorexant | |
MXPA05010506A (es) | Forma farmaceutica para el tratamiento de casos agudos y exacerbaciones de pacientes con artritis reumatoide, y transtornos agudos relacionados. | |
Jassem et al. | Ex vivo permeability study and in vitro solubility characterization of oral Canagliflozin self-nanomicellizing solid dispersion using Soluplus as a nanocarrier | |
KR20110029249A (ko) | 프란루카스트의 향상된 용해도를 갖는 약학적 조성물 | |
Tímea et al. | Nanonization of Niflumic Acid by Co-Grinding |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980135720.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09814279 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 211121 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010529625 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2737543 Country of ref document: CA Ref document number: MX/A/2011/002847 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009814279 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117008410 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011114292 Country of ref document: RU |